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Tuberculosis (TB) is the leading cause of death from infectious disease, and new drugs 
are needed to treat emerging resistant TB infections. Using genetic, metabolomic, 
crystallographic, and recombinant enzyme assays we discovered a compound that kills 
Mycobacterium tuberculosis (Mtb) upon binding the active site of 
phosphopantetheinyl transferase (PptT). PptT is an essential enzyme for Mtb, and has 
been a desired drug target for many years. PptT uses coenzyme A (CoA) as a substrate 
to activate acyl carrier proteins (ACPs) by transferring phosphopantheine (Ppt) from 
CoA onto the ACP. ACPs then use the Ppt group for synthesis of lipids critical for 
Mtb’s cell wall and virulence. The compound did not fully abolish PptT activity, and 
we found that killing of Mtb by the inhibitor depended on the activity of a newly 
identified enzyme, a Ppt hydrolase (PptH) that can remove Ppt from ACPs. While 
PptH is highly conserved among mycobacteria, it’s opposing function to an essential 
process has no obvious utility to the cell. This activity was revealed by a new 
mechanism of antimicrobial resistance: loss of function in an enzyme (PptH) that 
opposes the action of the enzyme (PptT) targeted by the inhibitor. The opposing 
PptT/PptH reactions invite exploration of a regulatory pathway in CoA physiology, as 
the two enzymes oppose each other and may be involved in stress-response signaling. 
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CHAPTER 1 
INTRODUCTION 
Mycobacterium tuberculosis (Mtb) has been a human pathogen for thousands of years. 
Mtb DNA has been amplified from archeological remains dating as far back as 9000 
years1, and some analysis has found evolutionary nodes in the Mtb genome that 
coincide with human migration out of Africa 40,000 years ago2. Archeological 
remains from almost any era tested have been found to contain forensic or genetic 
evidence of Mtb infection3. Degree of outbreak has waxed and waned over time, but it 
has been estimated that Mtb has killed more people throughout history any other 
microbial pathogen3. TB was especially lethal during the industrial revolution, with 
soaring population density in cities, notoriously terrible air quality, and rampant 
malnutrition, all at a time when epidemics were poorly understood4–6. Little was 
known about TB infection until 1865, when Jean Antoine showed that tuberculosis 
was infectious7. Knowledge was further increased in 1882, when Robert Koch 
presented on his discovery of bacilli and the Koch-Henle postulates. These findings 
helped shape modern understanding of bacteria and epidemics3,8. 
Based on the early research of Antoine and Koch, as well as research that came 
later, we now know that tuberculosis is very infectious, and primarily spread through 
aerosols produced from the coughing or sneezing of infected people. In classic TB 
infection, a host will inhale bacteria within aerosol droplets, and the bacteria will be 
deposited in the lungs9. Once inhaled, primary immune response involving 
macrophages may disseminate Mtb throughout the body, but pulmonary TB is the 
most common form of infection, and the majority of the bacteria are located in the 
lungs.  
A major mechanism of immune response to Mtb infection is to sequester the 
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bacteria in granulomas9. Granulomas are formed as necrotic cavities in the lungs, and 
are relatively isolated from the rest of the body. The host immune system can contain 
Mtb within granulomas more or less indefinitely, and many people who are infected 
with Mtb may live their whole lives unaware that they have been infected. 
Granulomas are often asymptomatic, but can be detected by chest X-ray, and are 
considered indicative of Mtb infection especially in the presence of other signs of Mtb, 
such as persistent cough10.   
It is estimated that 1/3 of the world’s population is infected with Mtb, and 
tuberculosis causes more deaths annually than any other infectious disease11–13. The 
WHO reported that there were about 1.7 million deaths from Mtb in 2016, and while 
this is a tragically large number, it is nowhere near estimates of the number of people 
infected worldwide. This is because although Mtb is extremely infectious and only a 
small number of bacteria are needed to establish an infection, about 90% of infected 
people never develop active TB12. When Mtb is sequestered within granulomas, it can 
enter a non-replicative state and remain dormant for the entirety of the host’s life. This 
stage of infection is called latent TB, and patients are not usually contagious when 
their infection is being managed by their immune system in this way12,14,15. In about 
10% of those infected, Mtb can reactivate, at which point the bacterial population is no 
longer being contained by the immune system and the bacterial burden of Mtb can get 
very high12. This rate can be higher in populations comprised of individuals who are 
malnourished or immunocompromised from HIV or diabetes, which are all risk factors 
for active TB infection. When people have active TB they are infectious and on 
average will infect 10-15 people per year of untreated infection15. Tuberculosis is 
challenging to treat now with modern drugs, but during the height of the “white 
plague” the only real option available was isolation in sanitoria6,16. 
 Sanitoria were developed in the mid-late 19th century, and for about 100 years 
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were the only treatment for tuberculosis- and then, only for those who could afford 
them17. The premise was that by isolating “consumptives,” or people infected with 
Mtb, sanatoria could help curb the spread of TB within cities, and could also provide 
better nutrition and ventilation, improving the outcomes of disease for infected 
patients3,6,17. We now know that clean/drier air, proper nutrition, and vitamin D 
exposure can improve the outcome for TB patients, but they are far less effective than 
antibiotics.  
 The first antibiotics discovered for TB treatment were streptomycin (1944) and 
para-aminosalicylic acid (PAS) (1946), closely followed by isoniazid (INH) and 
pyrazinamide in (PZA) 195218. It was quickly discovered that monotherapy for TB 
treatment was ineffective and could rapidly result in the emergence of resistant strains- 
this is likely a result of high bacterial burden in active TB cases. If the bacterial burden 
is higher than the frequency of resistance (FOR), a patient undergoing treatment is 
likely to have a naturally occurring subpopulation of bacteria that are resistant to the 
drug. For this reason, a standardized multi-drug therapy has been developed, because 
when multiple drugs with different targets are combined, their FOR becomes far 
higher than the possible bacterial burden during infection. Standard recommended 
treatment for drug-susceptible TB from the 2016 WHO report includes 2 months of 
daily treatment with rifampicin (RIF), INH, PZA, and ethambutol (EMB) followed by 
4 months of daily INH and RIF10. In the first 2 months of this treatment regime, the 
multi-drug therapy results in a conservative estimated FOR of 1 in 1018. PZA is not 
very effective against Mtb alone but is synergistic with the drug regime.  
Table 1 shows a summary of the 4 front line drugs for TB treatment and their 
activity, mechanism of action, and frequency of resistance. Streptomycin is not 
included but is sometimes used in place of EMB. Treatment targets active TB 
infection, as most of the targets are only essential in actively replicating cells. There is 
	4		
some dispute as to the efficacy of treatment on latent TB, and in most countries where 
rates of TB are high, resources are focused on the treatment of active infection14,19,20. 
Table 1: Summary of the 4 front line drugs for treatment of Mtb infection18,21 
Drug (year of 
discovery) 
MIC90  
(µg/ml) 
Mechanism of 
action 
Resistance 
genes 
Gene function FOR 
Isoniazid  
INH (1952) 
0.02-
0.2 
Inhibition of 
mycolic acid 
biosynthesis 
katG,  
inhA 
Catalase-
peroxidase , 
Enoyl ACP 
reductase 
10-5-10-6 
Rifampicin  
RIF (1966) 
0.05-1  Inhibition of 
RNA synthesis 
rpoB β subunit of 
RNA 
polymerase 
10-7-10-8 
Pyrazinamide 
PZA (1952) 
16-50 
(pH5.5) 
Depletion of 
membrane 
potential 
pncA Nicotinamidase/
pyrazinamidase 
10-5 
Ethambutol 
EMB (1961) 
1-5 Inhibition of 
arabinogalactin 
synthesis 
embB Arabinosyl 
transferase 
10-5 
  
Mtb treatment has been relatively effective at curbing outbreaks in modern 
Western cities. Unfortunately, resistance is on the rise. Despite the low frequency of 
resistance expected with standard treatment, there are a number of causes for the 
emergence of resistance. Many countries with the highest incidence of Mtb are 
developing countries with poor infrastructure, where people may have limited access 
to medical care. Diagnosis of TB may be low, and patients who are diagnosed with TB 
may not have a steady supply of drugs, or may not finish their course for other 
reasons. The minimum length of time for treatment is 6 months, and many people—
even those with steady access to healthcare—begin treatment but do not finish the full 
course 22,23. There can be many side effects from the TB treatment, including 
hepatotoxicity and gastrointestinal distress, which can cause patient noncompliance—
especially as many of the symptoms of pulmonary TB may disappear in the first 2 
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months24,25. The CDC reported 500,000 new cases of multi drug-resistant (MDR) and 
extensively drug-resistant (XDR) TB in 2016, though most TB cases are not tested for 
drug sensitivity so this number is likely underestimating the true extent of resistance23.  
 Once Mtb becomes MDR or XDR, it becomes much harder to treat. Second 
line drugs are not as effective and have much more severe side effects; additionally 
treatment time is expanded from 6-9 months to up to 32 months for XDR TB10. The 
lowered efficacy of the drugs also significantly reduces the chance of successful 
patient outcome; 50-60% success rate is common (Figure 1A), and the success rate 
for XDR TB treatment is even lower. In addition to the reduction in treatment success, 
MDR and XDR are exponentially more expensive to treat than drug-susceptible Mtb 
(Figure 1B). Resources for the treatment of TB are already limited, and the added 
costs of treating MDR and XDR TB realistically mean that fewer people can receive 
treatment for their infection. Additionally, MDR or XDR patients should ideally be 
isolated for part of their treatment to avoid spreading the resistant bacteria, but this can 
be challenging to achieve even if facilities are available for the isolation10,21. With a 
lack of effective options for XDR TB treatment and the infectious nature of TB, XDR 
TB has already begun to spread, and it will be extremely challenging to stop with our 
current drug arsenal.  Some doctors have even suggested bringing back sanitoria as 
viable treatment options, though their main benefit would be control, given the lack of 
alternatives26. 
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Figure 1: WHO and CDC graphics on patient outcomes and costs associated with 
MDR and XDR TB. (A) WHO chart following patient outcome of MDR TB 
treatment in various countries10. (B) Adapted CDC infographic on the side effects and 
costs associated with MDR and XDR treatments23. 
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 In the face of rising resistance rates, the global community needs to act sooner 
rather than later. One way to help prevent the spread of MDR or XDR TB is to 
introduce new drugs for treatment. With more frontline drugs that are as effective or 
better than current options, patients with MDR or XDR TB would not necessarily face 
a daunting multi-year battle for health. For these reasons we have focused our research 
on identifying new potential drug targets by studying the effects of drug-like 
molecules from chemical libraries.  
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Chapter 2: 
 
A high throughput screen uncovered X-B016178918, a compound that selectively 
kills replicating Mycobacterium tuberculosis 
Summary 
One method of identifying potential drug targets is to screen chemical libraries for 
compounds which produce a desired phenotype (e.g. cell death)1. After compounds 
that can kill bacteria have been identified, cells can be exposed to lethal concentrations 
of the compound of interest, and resistant colonies grown. The DNA from these 
colonies can then be sequenced to determine genetic mutations that may cause the 
resistance, thereby indicating the mechanism of resistance and possibly the mechanism 
of action. After testing compounds from Sanofi’s chemical library, one compound, X-
B016178918 (8918) was identified as a potential hit. 8918 was an attractive compound 
because the parent compound, proguanil, is a well-established drug, and 8918 
similarly did not have any major structural red flags. We found that 8918 was 
mycobacteria specific, and active on replicating Mycobacteria tuberculosis, as well as 
active in a highly acute mouse model of Mtb infection. We also observed that 8918 
appeared to have a distinct target from Mtb drugs, and that 8918-resistant mutants had 
mutations in rv2795c, a non-essential enzyme of unknown function, as well as 
rv2794c/pptT, a relatively well-characterized and essential enzyme in the same operon 
as rv2795c.    
 
Introduction 
As part of a broad-scale effort to uncover potential new targets and drug classes, our 
lab has been engaged in high-throughput screening of chemical libraries. We have 
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screened around 840,000 compounds in replicating and non-replicating assays, where 
Mtb is exposed to a test compound at a single concentration for 7 days, and the impact 
the compound has on growth is determined. Of those 840,000 compounds, 7800 had 
been shown to have activity against M. smegmatis or M. marinum whole cells, with 
unknown targets. Among that set of 7800 compounds with whole cell anti-
mycobacterial activity, we identified the compound X-B016178918 (8918). 8918 was 
initially considered a compound of interest in part due to its similarity to the parent 
compound proguanil, as shown in Figure 1. Proguanil is a well-established drug used 
to treat Plasmodium falciparum (malaria), and is considered a WHO essential 
medicine2. Proguanil is typically co-administered with atovaquone, as the two drugs 
synergize to disrupt the potential of the Plasmodium mitochondrial membrane3. This 
synergy and membrane potential disruption is considered the main mechanism of 
action of proguanil, but proguanil is also metabolized by the liver into cycloguanil, 
and cycloguanil can act as a Plasmodium dihydrofolate reductase inhibitor4. We 
hypothesized that 8918 may act as a dihydrofolate reductase (DHFR) inhibitor in Mtb.  
 
 
Figure 1: Structures of proguanil, 8918, and cycloguanil 
 
 8918 was also initially flagged as a compound of interest because of some 
apparent activity in non-replicating (NR) as well as replicating (R) conditions. The 
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vast majority of antibiotics are active on replicating bacteria, and compounds which 
can target cells that are not currently replicating are highly desired5,6. With potential 
dual activity and a hypothesized mode of action work was initiated to better 
understand the activity of 8918.   
Results 
The structure-activity relationship of 8918 against Mtb 
After 8918 was selected as a compound of interest, Sanofi began to examine the 
structure and to generate similar compounds in order to expand information about the 
structure-activity relationship (SAR) of the family. They found a narrow SAR, as the 
structure could not be modified in many ways without reducing activity. Wild-type 
(WT) Mtb was exposed to decreasing concentrations of proguanil, lidamidine, and 
8918 to determine the minimum inhibitory concentration (MIC) (Figure 2A). 
Lidamidine was of interest as it has a very similar structure to 8918, and is a 
commercially available anti-diarrheal drug7 (Figure 2B). 
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A. 
  
B.  
  
Figure 2: Activity and structure of 8918 and lidamidine (A) Activity of 8918 
(black circles), lidamidine (blue triangles), and proguanil (red squares on wild-type 
Mtb. (B) Structures of X-B016178918 and lidamidine.  
 
 Because of the structural similarity between lidamidine and 8918, we decided 
to include it in future studies as an inactive control to 8918. 
 
8918 activity is specific to Mycobacteria 
Before attempting to determine the target of a compound, it is helpful to know if the 
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activity is specific, as non-specific activity can indicate general toxicity and be 
challenging to analyze. Additionally, it is helpful to have antibiotics that are as narrow 
spectrum as possible, so that incidental resistance does not occur. Because many 
people do not know they are infected with Mtb, if an antibiotic is active against other 
common infections it is likely a patient may take the drug to treat a non-mycobacterial 
infection, thus accidentally selecting for resistant Mtb in undiagnosed infection8. 
Additionally, standard treatment for Mtb infection is prolonged, and broad spectrum 
antibiotics can wreak havoc on the gut microbiome, dysbiosis of which has been 
linked to a number of health problems that can be exacerbated by the impact of 
antibiotic treatment9,10. 8918 was tested against Candida albicans, Pseudomonas 
aeruginosa, Escherichia coli, Staphylococcus aureus, Mycobacterium smegmatis, 
BCG (attenuated strain of Mtb) and Mycobacterium tuberculosis. We found that 8918 
was only active against Mycobacteria species, and the MIC90 for non-mycobacterial 
strains was above 100 µM, as indicated in Table 1. This indicates a narrow spectrum 
of activity for 8918. 
 
Table 1: Summary of MIC90 data for several bacterial species 
MIC90 (µM) of 8918 
C. albicans P. aeruginosa E. coli S. aureus M. smegmatis BCG M. tuberculosis 
>100 >100 >100 >100 0.78 6.25 3.13 
 
Investigating the activity of 8918 against replicating and non-replicating Mtb 
The potential dual activity of 8918 (active in both replicating and non-replicating 
conditions) was of great interest, and we investigated the activity of 8918 further. 
Beginning with replicating conditions, we saw that 8918 is very active against 
replicating Mtb, and after exposing cells to decreasing concentrations of 8918 we were 
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unable to recover any colonies at high concentrations to the limit of detection (Figure 
3A). We also observed that cell death caused by 8918 was time dependent, though 
activity was observed after two days of treatment, more death was observed at later 
time points. Interestingly, we saw that when cells were grown on agar plates 
containing charcoal we were able to recover colonies at higher concentrations, and that 
there appeared to be a baseline population of cells that survive treatment regardless of 
8918 concentration (Figure 3B). When charcoal is added to plates it can absorb 
compounds that may be carried over from treatment conditions into outgrowth 
conditions11. These results may indicate that 8918 is carried over when cells are 
transferred onto the outgrowth plates.  
 We next examined the activity of 8918 on cells that are non-replicating. Our 
lab typically uses an NR model which includes four stresses; hypoxia, butyrate as the 
main carbon source, acidic pH, and presence of reactive nitrogen species6. These 
stresses are similar when Mtb is inside of immunologically active macrophages, which 
is a critical process during Mtb infection, as discussed previously12. When cells in the 
4-stress NR media were exposed to 8918 and then plated on standard 7H11 agar 
plates, a reduction in colony-forming units was observed (~1.5 log10), indicating that 
there was some activity against cells in this NR model (Figure 3C). However, when 
the experiment was repeated and the bacteria were plated on 7H11 containing charcoal 
this effect was ameliorated (Figure 3D). This again indicates that 8918 can be carried 
over by the cells when they are removed from treatment conditions, but that charcoal 
is effective in absorbing the compound and preventing cell death during outgrowth. 
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Figure 3: Activity of 8918 against Mtb in non-replicating conditions, and the 
impact of charcoal on outgrowth. (A) Colonies found after treating replicating Mtb 
with 8918 after 2, 4, and 8 days on standard 7H11 plates. (B) Colonies found after 
treating replicating Mtb with 8918, recovered on 7H11 plates containing charcoal. (C) 
Activity of 8918 on 4-stress non-replicating Mtb, recovered on standard 7H11 plates. 
(D) Activity of 8918 on 4-stress non-replicating Mtb, recovered on 7H11 plates 
containing charcoal. (E) Activity of 8918 on PBS starved non-replicating Mtb, 
recovered on 7H11 plates containing charcoal. (F) Activity of 8918 on hypoxic (O2 < 
0.1%) non-replicating Mtb, recovered on 7H11 plates containing charcoal. 
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There are many methods of inducing a non-replicating state, and 8918 was also 
tested against Mtb in severe hypoxia and Mtb which has been starved in phosphate 
buffered saline (PBS) for one month. In both cases, 8918 was not active. Taken 
together, these data indicate that 8918 is active in replicating conditions, but not non-
replicating conditions. 
 
Testing impact of 8918 on folate biosynthetic pathway 
Proguanil toxicity against Plasmodium is achieved by inhibiting folate biosynthesis, 
through inhibition of dihydrofolate reductase (DHFR). We hypothesized that 8918 
may be impacting the same pathway in Mtb. Para-aminosalicylic acid (PAS) is an 
antibiotic for Mtb, typically used as a second line drug in resistant infections13.  PAS 
kills Mtb by inhibiting folate biosynthesis. It does so by mimicking the structure of p-
aminobenzoate (PABA) thereby acting as a pseudo-substrate of dihydropteroate 
synthase (DHPS) as the PAS structure can be incorporated into downstream products 
that are inactive due to the substitution of PABA for PAS14,15. Additionally, PAS 
toxicity can be rescued by the addition of methionine, serine, and glycine, as the 
presence of an excess of these amino acids can bypass incorporation products of the 
toxic PAS metabolites16. Because proguanil and PAS are active in the same pathway, 
albeit different organisms (malaria vs Mtb), we tested if supplementing with 
methionine, serine, and glycine could rescue Mtb growth inhibition caused by 8918 
treatment, as we hypothesize that 8918 inhibition would also be upstream of the amino 
acid rescue. We saw that although we could rescue the growth inhibition caused by 
PAS by supplementing with the three amino acids, there was no difference in toxicity 
of 8918 against Mtb (Figure 4). This indicates that 8918 is not inhibiting folate 
biosynthesis in Mtb.  
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Figure 4: Impact of amino acid supplementation during 8918 treatment. Para-
amino salicylic acid (PAS) inhibition of growth (closed triangle) can be rescued by the 
addition of methionine, serine, and glycine pH 7 (open triangle). 8918 growth 
inhibition (closed circle) is not impacted by the presence of methionine, serine, and 
glycine (open circle). 
 
8918 is active in acute mouse model of Mtb infection, moderately active in chronic 
mouse infection. (Performed by Isabelle Blanc at Sanofi) 
One challenge of drug development is that an active compound in vitro may not be 
active when it is used to treat infection with an in vivo model. Once a drug is 
administered, first- and second-pass metabolism may alter the drug, or distribution of 
the drug may never allow for concentrations to become inhibitory at the desired target. 
Enzymes may be essential in vitro and seem like good drug targets, but may not be 
essential in vivo. Finally, while compounds may be tested for toxicity on mammalian 
cell lines, such as liver originating HepG2 cells, toxicity may be impossible to predict 
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until tried in a live organism.  
When 8918 was tested in mice acutely infected with Mtb (106 bacteria, via 
nasal innoculation), it was metabolized quickly, but activity was observed at higher 
doses. Co-administration with aminobenzotriazole (ABT), a CYP450 inhibitor which 
helps reduce metabolism, allowed for activity of 8918 at lower doses (Figure 5). This 
indicates that 8918 has favorable chemical properties allowing it to maintain 
concentrations sufficient for antibacterial activity at the site of Mtb infection, and that 
the target of 8918 is essential for the survival of Mtb during infection.  
  
Figure 5: 8918 activity during acute mouse infection. Colony forming units (CFU) 
per lung of mice infected with high bacterial burden of Mtb after 10 days of treatment. 
Experiment performed by Isabelle Blanc, Sanofi. 
 8918 was also tested in a chronic mouse infection model, where mice are 
infected with a low number of bacteria and infection progresses for a longer period of 
time. In this model, 8918 normalized lung weight to the level of PZA treated mice 
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(Figure 6A). However, there was a modest (0.6 log10) reduction in CFUs recovered 
from lungs (Figure 6B).  
A. 
  
B. 
  
Figure 6: 8918 activity during chronic mouse infection (A) treatment with 50 
mg/kg and 100 mg/kg of 8918 normalized lung weight (g) to similar levels as PZA 
during chronic infection. (B) high doses of 8918 reduced recoverable CFUs modestly 
(0.6 log10) but to a lesser degree than PZA in the chronic mouse model. Experiment 
performed by Isabelle Blanc, Sanofi. 
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Selecting for resistant mutants to find genetic determinants of resistance 
In order to determine how 8918 kills Mtb, we decided to generate and analyze 
resistant mutants. Bacteria have natural rates of mutation in all genes, which can vary 
depending on the fidelity of the species’ DNA polymerase, and the impact the 
mutation has on cell viability. For this reason, a large population of bacteria tends to 
have a wide variety of mutations, some of which may confer resistance to a given 
stress or drug. This property of bacterial populations makes multi-drug therapy 
necessary for Mtb treatment, but it can be used advantageously to determine the 
mechanism of resistance to a compound. When Mtb is exposed to lethal 
concentrations of a compound, the members of the population that have a mutation 
that enables resistance will grow, and the genomes of these colonies can be sequenced 
to identify mutations which may have caused the resistance. This can implicate the 
mechanism of resistance, which in turn can elucidate the target, though sometimes 
resistance mutations are non-specific. We generated resistant mutants in Mtb as well 
as Mycobacterium smegmatis (Msm), which is a non-pathogenic and fast-growing 
species of Mycobacteria. 12 colonies were selected from each species and analyzed 
for mutations. The summary of these data is found in Table 2 and Table 3. 
Interestingly, Msm mutant selection was done at 10x the MIC and it was possible to 
isolate resistant mutants. By contrast, Mtb mutant selection was done at 4x and 8x the 
MIC, but only the 4x MIC plates produced mutants. No Mtb colonies were observed at 
8x the MIC of 8918. 
 
 Table 2: Summary of resistant Msm mutants isolated. Including MIC to 8918, 
RIF, and EMB, as well as the gene suspected to cause resistance. Asterisks denote 
strains which were whole genome resequenced; other mutations were found by PCR 
and sequencing of gene 
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MIC90(µM) 
 
8918 Rif EMB Gene mutated 
WT 0.78 6.25 1.56 none 
A1 50 3.13 1.56 msm_2647 G206V 
A2* 25 3.13 1.56 msm_2647 9 bp deletion 
A3* 50 3.13 1.56 msm_2647 D161E 
A4 50 3.13 1.56 msm_2647 Y97D 
A5 50 3.13 1.56 msm_2647 D120N 
A6 100 3.13 1.56 unknown 
B1 25 3.13 1.56 msm_2647 D120N 
B2 >100 3.13 3.13 msm_2647 9 bp deletion 
B4* 6.25 3.13 1.56 msm_2647 Y97D 
B5 >100 6.25 1.56 msm_2647 D161E 
B6* >100 3.13 3.13 msm_2647 9 bp deletion 
. 
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Table 3: Summary of resistant Mtb mutants isolated. Including MIC90 to PAS, 
INH, 8918, RIF, EMB and MOXI and the gene suspected to cause resistance. Clones 
denoted with an asterisk were whole genome resequenced; other clones were analyzed 
by PCR and sequencing of the genes of interest.  
 
 MIC90 (µM) 
MT PAS INH 8918 RIF EMB MOXI Gene mutated 
WT <.05 0.39 3.125 0.1 6.25 <.02 none 
A1* <.05 0.39 >100 0.2 3.125 <.02 rv2795c H246N 
A2 <.05 0.39 >100 0.1 3.125 <.02 rv2795c H246N 
A3 <.05 .39 >100 0.1 6.25 <.02 rv2795c H246N 
A4 <.05 0.39 >100 0.1 6.25 <.02 pptT (rv2794c) W170S 
A5 <.05 0.39 >100 0.2 6.25 <.02 rv2795c G266V 
A6* 
 
0.1 0.39 >100 0.2 6.25 <.02 rv2795c V203F 
B1* 0.1 0.39 100 0.2 6.25 <.02 pptT W170L 
B2* .20 1.56 >100 0.2 6.25 <.02 rv2795c G266V 
B3* 0.1 0.39 >100 0.1 6.25 <.02 rv2795c R321R, H246N 
B4* 0.20 0.39 >100 0.2 6.25 0.04 rv2795c D51E 
B5 0.1 0.39 >100 0.1 6.25 <.02 rv2795c D24N 
B6 <.05 0.39 >100 0.1 6.25 <.02 rv2795c A41G 
 
 The frequency of resistance (FOR) found against 8918 was 7x10-7 in Msm and 
3x10-7 in Mtb, a similar FOR for both species, and an FOR that is comparable to TB 
antibiotics17. Of note is that none of the 8918 resistant mutants had cross-resistance to 
standard Mtb drugs, which may indicate that 8918 is inhibiting a different target, and 
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that the resistance observed was specific to 8918. rv2795c (Mtb) and its Msm 
homolog msm_2647 was by far the most commonly mutated gene, present in all Msm 
mutants and 10 out of 12 Mtb mutants. pptT was found to be mutated in 2 Mtb clones, 
with the same amino acid residue mutated in both. Later work with a summer student 
(Raphael Kirou) uncovered an 8918 resistant Msm mutant with a P67 mutation in the 
pptT homolog msm_2648. rv2795c and pptT are predicted to be in the same operon, 
and have a small overlap of sequences.  
 
Discussion 
Taken together, these data indicate that 8918 kills Mtb through a novel and 
Mtb-specific target. We observed that 8918 did not kill non-mycobacterial species in 
an antimicrobial spectrum screen. Further, clones resistant to 8918 had no cross 
resistance to any Mtb drugs tested, which led us to suspect that resistance to 8918 was 
specific, i.e. not caused by non-specific efflux or increased metabolism into a non-
toxic structure. We also hypothesized that the target is different from the Mtb drugs 
tested, as otherwise mutations in the same target may have resulted in cross resistance. 
Initially 8918 was chosen as a compound of interest because of its structural similarity 
to proguanil, and the possibility that 8918 could be acting as a dihydrofolate reducase 
inhibitor. Because 8918 inhibition was not rescued by addition of methionine, serine, 
and glycine, as dihydrofolate synthesis inhibition caused by PAS can be, we also 
hypothesized that 8918 has a mechanism of action distinct from proguanil, despite 
their structural similarities. We therefore hypothesize that 8918 has a target distinct 
from RIF, EMB, INH, PAS, MOXI, and proguanil.   
8918 appears to be active specifically on replicating Mtb. We tested a variety 
of conditions that induce non-replication and saw that 8918 did not kill in hypoxia, 4-
stress, or PBS starved cells. It was interesting that there was a significant difference 
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when cells were grown on plates with or without charcoal after treatment. In 
replicating cells, outgrowth on standard 7H11 plates showed a strong reduction in 
CFUs, with no colonies recoverable to the limit of detection at high concentrations of 
8918. By contrast, outgrowth of an identically performed exposure on 7H11 plates 
containing charcoal showed that although 8918 did lead to a multi-log10 reduction of 
CFUs, there was a concentration independent population of about 104 cells that were 
constant and not impacted by treatment. These cells may represent a persistent 
population, and the activity of 8918 specifically on replicating cells may indicate that 
these cells were non-replicating persisters in the original treatment conditions18,19. The 
large reduction of CFUs observed on regular 7H11 plates during outgrowth from NR 
exposure indicates that 8918 might stick to cell membranes or be taken into the cells at 
relatively high levels during non-replication. Then, when the cells are plated onto 
7H11 without charcoal and start to replicate again, 8918 is present in sufficient 
concentrations to kill the cells and reduce the recoverable CFUs. When cells are plated 
on 7H11 with charcoal, the charcoal can absorb the 8918 that is carried over inside or 
on the cell membrane, and at higher doses the approximately 104 cells that are killed 
by carryover on regular 7H11 plates are able to grow. In the case of NR cells treated 
with 8918, it appears that any activity observed in the conditions tested may be 
attributed to the carryover of compound into outgrowth, and not any activity of the 
compound on non-replicating cells—again, because there appears to be no activity 
when the outgrowth is performed on 7H11 plates containing charcoal.  
The results that 8918 is active in the highly acute mouse model and moderately 
active in the chronic model are encouraging. It is common for compounds to kill Mtb 
in vitro and then have no activity in vivo. It is also significant that 8918 is metabolized 
rapidly in mice, however, there is still a high enough concentration for a long enough 
time to reduce the bacterial burden in infected mice. This indicates that the target is 
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vulnerable to in vivo inhibition, and therefore is essential for in vivo survival of Mtb. 
Not all genes are essential in all conditions, and sometimes a gene essential in vitro is 
not essential during infection. The activity of 8918 in mice indicates that the target is 
vulnerable and druggable, and confirms that pptT is essential in vivo, which has been 
shown before by attenuated infection in mice with a conditional knockdown of pptT20. 
Finally, the mutations found in resistant clones were relatively consistent, 
indicating that Mtb and Msm had similar frequencies of resistance and that they 
tended to become resistant to 8918 through mutations in homologous genes. rv2795c 
encodes a gene of unknown function, which is predicted to be non-essential through 
transposon mutagenesis21. As a non-essential enzyme, we hypothesized that it was not 
the target of 8918, but most likely had a role in the mechanism of resistance of these 
resistant clones, especially as the Mtb resistant strains with rv2795c mutations were 
highly resistant to 8918, and many of the strains sequenced did not have other 
mutations which could logically have resulted in resistance. The frequency of 
mutations in rv2795c supports the inference that the enzyme is non-essential, as 
mutations in non-essential enzymes are less likely to cause growth defects or prevent 
growth, and therefore may persist in higher numbers throughout a cell population after 
they occur. Random mutations in non-essential enzymes are far more likely to be loss 
of function, as opposed to gain of function. Additionally most of the mutations we 
observed in rv2795c impacted amino acids located in the predicted active site and 
predicted to be involved with magnesium binding, which in turn was the predicted ion 
involved in catalytic activity, and so we hypothesize that mutations in rv2795c result 
in loss of function of the enzyme, which can enable the cells to become 8918 resistant.  
By contrast, Phosphopantetheinyl transferase (PptT) is an essential enzyme, 
and has been a desired drug target for several years21,22. PptT uses Coenzyme A (CoA) 
to catalyze the activation of precursors for the synthesis of many essential cellular 
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products, including mycobactins and mycolic acids, which as the names suggest are 
characteristic mycobacterial products. The identification of mutations in pptT in 8918 
resistant Mtb and Msm suggest that it likely may be the target. The frequency of 
mutations found in pptT was much lower; this is notable because it may indicate that 
although the frequency of resistance of 8918 was around 10-7, the frequency of 
mutation of pptT may be closer to 10-8, which is a very low frequency of resistance 
and is comparable to the FOR for RIF17,23. If it is possible to negate the mechanism of 
resistance caused by rv2795c, it may be possible to reduce the FOR of 8918 about 10 
fold.  
 
Materials and Methods 
Antimicrobial spectrum:  
Escherichia coli: Cells were grown in Middlebrook LB broth from a frozen 
stock at 37°C with shaking overnight. Cultures were then diluted to OD580 0.01 and 
plated into 96 well plates for experimental groups to be added. Compound and 
control (meropenem, MIC90 = 3.13 µM) dissolved in DMSO were added at varying 
concentrations. The plates were incubated at 37°C with shaking for 3-5 hours, at 
which point the OD580 was taken.  
Pseudomonas aeruginosa: cells were grown overnight in Middlbrook LB broth 
from a frozen stock at 37°C with shaking. Cultures were diluted to OD580 0.01 and 
plated into 96 well plates, data collected after 4-5 hours. Moxifloxacin (MIC90=0.8 
µM) was used as a control.  
Candida albicans: cells were grown in YM media (pH 4.0) at 30°C without 
shaking, in aerated tissue culture flasks for 36 hours. Cells were diluted to OD580 0.01, 
plated into 96 well plates and exposed to compound. After 36 hours the cells were 
mixed and the OD580 taken, nystatin (MIC90= 1.6 µM) was used as a control.  
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Staphylococcus aureus: Cells were grown from frozen stocks in Mueller 
Hinton media overnight at 37°C with shaking. After diluting to OD580= 0.01 cells were 
exposed to compounds, and shaken at 37°C for 3-5 hours before again taking the 
OD580. Moxifloxacin (MIC90=0.1 µM) or Rifampicin (MIC90=0.01 µM) were both 
used as controls. 
 
Mouse infections 
All mouse infection experiments were performed by Isabelle Blanc at Sanofi 
Highly acute mouse model:  
Balb/C 5 week old female mice were infected with 1x106 colonies of H37Rv 
Mtb (Day 0). Infection method was via nasal inhalation of liquid Mtb culture. The 
next day (Day 1) lungs were harvested from some mice as Day 1 lungs. The remaining 
mice were treated with either the experimental compound (8918) or rifampicin as a 
control. Mice were treated every weekday by oral gavage, and lungs were harvested 
on Day 11 as the final endpoint for the experiments. Lungs were homogenized and 
plated for CFUs. 
 
Chronic mouse model:  
Balb/C 5 week old female mice were infected with 102 CFU of H37Rv Mtb. 
Lung samples were collected from small cohorts of mice at day 3 and day 28, at which 
point (day 28) treatment was initiated once a day on weekdays via oral gavage for an 
additional 25 days, at which point the experiment was ended and lungs collected for 
homogenization and plating for CFUs. 
 
Replicating and non-replicating MIC or CFU 
H37Rv Mtb was the strain used for all experiments. Replicating cultures were 
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grown in Middlebrook 7H9 media supplemented with 0.2% glycerol, 10% 
Middlebrook OADC growth supplement, and 0.02% tyloxapol. Cultures were grown 
at 37°C. Non-replicating cultures were produced by washing replicating cultures twice 
in an equal volume of PBS and 0.05% tyloxapol. Cells were then resuspended in a 
modified Sauton’s minimal media (0.05% ammonium sulfate, 0.05% monopotassium 
phosphate, 0.005% ferric ammonium citrate, 0.05% magnesium sulfate, 0.01% zinc 
sulphate, 0.02% tyloxapol, and 0.05% butyrate at pH 5. To determine CFUs Mtb was 
plated on Middlebrook 7H11 plates supplemented with 10% OADC supplement and 
0.5% glycerol, and with 5 g/L charcoal, if charcoal was required.  
 
Mutant selection of 8918 resistant Mtb and Msm 
Msm: 7H11 plates were prepared containing 0.2% glycerol and 19.3 µM 8918 
(10x the MIC). Cultures were grown in Middlebrook 7H9 media supplemented with 
0.2% glycerol and 0.02% tyloxapol, at 37°C with shaking. Cells were then spun down 
(4000 RPM) and resuspended at a high concentration, such that 108 cells could be 
plated in 100uL. This concentrated cell stock was then used to make a dilution such 
that 107 cells could be plated in 100uL. The original inoculum was plated on 7H11 
plates not containing 8918 at the time of plating to calculate the FOR. After resistant 
colonies were selected, they were restreaked on plates containing the same 
concentration of 8918 the cells were originally selected on to confirm resistance, 
followed by testing the MIC90.  
Mtb: 7H11 plates were prepared containing 0.2% glycerol, 10% OADC, and 
12.5 µM 8918, or 25 µM 8918 (4x and 8x the MIC, respectively) 108 and 107 cells 
were also used as the number of cells plated on each agar plate. Colonies selected for 
further testing were restreaked on plates containing 12.5 µM 8918 to confirm 
resistance, then grown in liquid 7H9 media and tested for MIC against 8918.  
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Chapter 3 
Metabolomics indicate 8918 can alter CoA metabolism 
Summary 
We used metabolomics as a tool to identify the pathway(s) targeted by 8918 activity. 
We also suspected the Rv2795c may be inactivating or metabolizing 8918 in some 
way, leading to high-level resistance when the gene is mutated. Thus, we wanted to 
know if 8918 was acting as a pro-drug, being metabolized to a significant degree, and 
if we could identify potential active metabolites as a result. We found that 8918 does 
not appear to be significantly metabolized in WT or the rv2795c mutant strain, and 
therefore is likely not a pro-drug. We also observed that the high MIC50 of lidamidine 
does not appear to be related to the ability of lidamidine to enter the cell. Finally, we 
saw that CoA biosynthetic pathways seemed to be most impacted by 8918 activity, 
which is consistent with the hypothesis that PptT is the target.  
 
Introduction 
Metabolomics can be an effective tool to understand what happens to cellular 
metabolism when inhibition from a drug is occurring. If a drug has a specific target, 
inhibition of this target can manifest itself by increases or decreases in metabolites 
around the impacted enzyme or enzymes. We wanted to examine metabolism of 8198 
itself between WT and MT strains of Mtb, as well as the changes that occurred in 
cellular metabolites inside the cells. In order to study the way 8918 works, we first 
looked at compound uptake. To this end, we used a “swimming pool” assay method, 
in which cells are placed on filters that can then be exposed to compounds for a short 
period of time before being lysed and examined for metabolites (Figure 1). We 
compared WT and MT Mtb, as well as the impact of 8918 on WT Mtb at a variety of 
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8918 concentrations.  
 
 
Figure 1: Overview of metabolomics experimental set-up. After lysate is generated 
it is injected for mass spectrometery (MS) analysis  
Results 
Determining appropriate concentration of 8918 for metabolomic experiments 
Before setting up experiments to examine relative metabolite concentrations we 
wanted to ensure that we knew what concentrations of 8918 were likely to be sublethal 
or lethal on the filter setup. Because the filters are inoculated with 1 mL of OD580 1 
and are then grown on agar for a week, the inoculum for the experiment is very high, 
which is necessary to get metabolite concentrations high enough for detection. We had 
previously observed that 8918 had an inoculum effect at high concentrations of cells, 
which resulted in a much higher than normal MIC1. Additionally, the MIC in agar vs 
liquid media may be slightly different. We made agar plates with concentrations 
ranging from 10-50 µM 8918 and placed the filters with the 1 mL cell mat on the 
plates. We observed that 40 µM 8918 over a week was growth inhibitory to the cells, 
and selected 40 µM as our baseline concentration for experiments.  
 
Examining metabolism of 8918 in WT vs MT cells 
Initially we hypothesized that Rv2795c activates 8918, and therefore loss of function 
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mutations in rv2795c could lead to resistance from 8918 no longer being metabolized 
into its lethal form. To this end we set up a metabolomics experiment comparing 
uptake and metabolism of WT Mtb and the rv2795c H246N mutant strain of Mtb, with 
40 µM 8918, and with 40 µM proguanil as an inactive control. We observed that both 
compounds seemed to be taken up readily into the cells, as demonstrated by high 
levels of compounds detected from the filter/cell fraction, and very little compound 
remaining in the swimming pool section of the experimental setup (Figure 2A-B). We 
also observed that there was not a significant difference in recoverable 8918 or 
proguanil between the WT and MT strains of Mtb. (Figure 2C-D). As there was no 
significant loss of recoverable 8918 between MT and WT strains, we hypothesized 
that the resistance mechanism was not related to loss of function of an activating 
enzyme. Additionally, no significant levels of 8918 metabolic products were 
detectable in the MS data, and only minor amounts of methylated and hydroxylated 
8918 were observed in both WT and MT Mtb, further indicating that 8918 was not 
being significantly metabolized in either strain. 
  
	38		
 
 
 
 
 
 
 
 
Figure 2: Detection of 8918 and proguanil in cells vs swimming pool fractions (A) 
Area under the curve (AUC) ion counts for 8918 and proguanil, in WT (blue) and MT 
(red) strains recovered from the Mtb cells. (B) AUC ion counts for 8918 and 
proguanil, in WT (blue) and MT (red) strains, recovered from the swimming pool 
section (separate from cells). (C) AUC ion counts for media (red) and cell 
(lysate)(blue) fractions together for 8918 in MT and WT strains. (D) AUC ion counts 
for media (red) and cell (lysate)(blue) fractions together for proguanil in MT and WT 
strains. Experiment and analysis done with the help of Madhumitha Nandakumar. 
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Figure 2 continued 
D. 
 
We next wanted to observe more broadly the impacts of 8918 on cell 
metabolism, to identify what pathway was being impacted. In this experiment we used 
20, 40, 200, and 400 µM of 8918 as the active compound concentrations. A dose curve 
was performed as dose-dependent changes in metabolites provide evidence that any 
changes observed are related to the activity of the compound. Additionally, lidamidine 
and proguanil were selected in this experiment as inactive controls. Lidamidine has a 
more similar structure to 8918 than proguanil, and we wanted to test if it was also a 
good inactive control in metabolomics. We first observed that out of the 3 compounds, 
8918 accumulates inside cells to a far lesser degree, again indicating that the inactivity 
of proguanil and lidamidine is not related to an inability to get inside Mtb (Figure 3). 
The amounts recovered were slightly lower but still comparable to the first 
metabolomics experiment tried (Figure 2).  
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Figure 3: AUC at 0, 20, 40, 200, and 400 µM. AUC of lidamidine (black) proguanil 
(grey) and 8918 (red) recovered from cell lysates in metabolomics experiment.  
 
 When we moved into a more general analysis, we were looking to see if we 
could find peaks which were dose-dependently accumulated or depleted after 8918 
treatment, but not in lidamidine or proguanil treated cells. Metabolites that are 
accumulated across all treatment groups may be related to the compound structure (off 
target effects) but not the actual activity of the compound. We found that while a 
number of metabolites were recoverable, only a small number were modified dose 
dependently by 8918 alone (Figure 4).  
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Figure 4: Heatmap of metabolites observed in this experiment. Concentrations are 
in triplicate, increasing in concentration starting with 8918, followed by lidamidine, 
then proguanil. (normalized to untreated cells). Color gradient are scaled by Log2 and 
range from -6 to +6 based on color intensity, with green representing depletion (down 
to -6 log2 and red representing accumulation up to 6 log2.  
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 Upon further analysis of compounds that were dose dependently impacted by 
8918 treatment, we found methyl citrate, malate, propionyl CoA, and 2-
dehydropantolactone as the only significant accumulations after 8918 treatment 
(Figure 5 A-C). Methyl citrate and propionyl CoA in particular had striking 
accumulations, increasing from barely detectable in untreated cells. We also observed 
depletion of some metabolites: 3-hydroxypropionyl-CoA and R-pantoate showed 
depletions after 8918 treatment.  
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Figure 5: Graphs of dose-dependent and 8918-induced metabolite changes. AUC 
graphs of 8918 (red line; black circles), lidamidine (black line; black squares), and 
proguanil (grey line; black triangles). These metabolites represent all the metabolites 
found which were measureable and dose-dependently impacted by 8918 treatment.  
 
We were interested to see that lidamidine appeared to generate an intermediate 
metabolic profile, between proguanil and 8918, and hypothesized that lidamidine 
might inhibit the same target as 8918 but to a lesser degree. We tested the MIC of 
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lidamidine at a higher concentration, and saw that high concentrations of lidamidine 
could inhibit cell growth of WT Mtb (Figure 6). Lidamidine may be a relatively poor 
inhibitor, but the high degree of accumulation within the cell may be sufficient to 
inhibit the target at very high doses.  
 
Figure 6: Inhibition of WT Mtb by 8918 (black circles) and lidamidine (red squares). 
At 100 µM lidamidine does not appear to inhibit Mtb at all, but at 125 µM lidamidine 
has an MIC50 
 
 When the dose-dependently altered metabolites are placed in a connected 
metabolic map, it becomes apparent that while they may not complete a metabolic 
pathway, they can be placed relatively near each other. Most notably, they can all be 
related within a few metabolic steps of CoA (Figure 7). This is significant because 
PptT, the gene of which was found mutated in 8918-resistant Mtb, uses CoA as a 
substrate, and we hypothesize that inhibition of PptT would result in downstream or 
upstream changes to CoA precursors.  
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Figure 7: Schematic overview of all dose-dependent and 8918-specific metabolite 
changes observed. Green represents depletion of metabolites, and red represents 
accumulation. CoA is indicated in fuchsia. 
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Discussion 
At this point it seemed as though Rv2795c was not metabolizing 8918, as mutations 
causing high levels of resistance to 8918 did not result in any changes in the 
metabolism of 8918. The fact that proguanil and lidamidine also appear to accumulate 
within cells at high concentrations indicates that the lack of bactericidal activity from 
the compounds is most likely due to lack of engagement with the target, though 
growth inhibition at high concentrations and the intermediate metabolic profile 
observed with lidamidine indicates that lidamidine may be a weak inhibitor of PptT. 
Similarly, the high degree to which the compounds enter the cells (or at least are 
associated with the cells, perhaps stuck in the membrane) also supports the finding 
that there appears to be a large degree of carryover during outgrowth experiments, as 
shown by the differences between standard and charcoal CFUs in chapter 2. If 8918 
(and similarly structured proguanil and lidamidine) accumulate inside the cells, it 
could explain why charcoal is necessary to get accurate CFU counts in outgrowth 
experiments. We also saw that 8918 appeared to accumulate within cells to a lesser 
degree than lidamidine or proguanil; this may be due to 8918 being mycobactericidal 
while the other compounds are not, as there may be no benefit to metabolizing or 
pumping out non-toxic compounds. One caveat to this observation is that due to the 
experimental setup, the cells were lysed but there was no distinction between 
membrane and intracellular areas, so we hypothesize that uptake was high but 
compounds may also just be associating with the cell membrane. We observed high 
amounts of lidamidine associated with cells but it is possible this accumulation is a 
combination of membrane association and intracellular concentration. Either way, 
8918 is found in lower concentrations, but lidamidine may stick to the cellular 
membrane to a higher degree.  
While 8918 did cause significant dose-dependent changes in metabolites, 
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Figure 5 also shows that lidamidine sometimes had an intermediate change compared 
to 8918. This may indicate that although lidamidine does not kill Mtb, it may partially 
inhibit the target. If lidamidine is less inhibitory than 8918, and it does appear that 
effects can only be seen at very high concentrations, it may be possible that lidamidine 
would not cause the cells to die. By contrast, proguanil did not have any dose-
dependent metabolic profile, indicating that proguanil does not cause any significant 
changes in metabolites even at high concentrations.  
When placed on a metabolic map showing CoA conversions and precursors, it 
is notable that the metabolites with significant and dose-dependent changes after 8918 
exposure are observed relatively close together, and are related to CoA metabolism. 
However, many CoA metabolites were not observed or were not significantly changed 
upon 8918 treatment. Some metabolites (such as CoA) may degrade quickly and be 
difficult to observe in the experiment as it was done. Some metabolites are challenging 
to capture with this method, and may not be detectable by this method. Additionally, 
some metabolites have no standards available, and definitive or confident 
identification of a peak may be impossible without a proper standard to use as a 
control. Other metabolites may be present in concentrations too low to detect, and 
accumulations or depletions, while significant if they occur, may still not be large 
enough to be detected at our level of sensitivity when run through mass spectrometry 
analysis.  In those cases it may be possible to detect changes with a much higher mass 
of cells than were used in this experiment.  
Ultimately, metabolic changes may not be easily predictable. Because cellular 
metabolism exists as an interchanging system of pathways, it is very possible for 
inhibition of an enzyme to manifest in accumulations or depletions further upstream or 
downstream of the target than may be easily rationalized. Some metabolites may be 
toxic, and accumulation exacerbates problems initiated by the activity of the toxic 
	50		
compound. As a result, the toxic metabolite may be rapidly metabolized into 
something that is less toxic when accumulated. Subject to these caveats, these data 
support that 8918 activity impacts metabolism related to CoA, and generally causes 
accumulation of CoA precursors, which fits our hypothesis that PptT is the target of 
8918.  
Materials and Methods 
Metabolomics  
H37Rv Mtb was grown to OD580 1 in standard 7H9, and then 1 mL was added to a 
nylon Durapore 0.22 µm nylon filter. Once the media had been filtered out, the filter 
with Mtb was placed on top of Middlebrook 7H11 plates supplemented with 0.2% 
glycerol and 10% OADC. Filters were incubated at 37°C for 1 week, until biomass 
had significantly increased. Filters were then transferred onto swimming pools 
containing 3 mL of 7H9 media with 0.2% glycerol (no tyloxapol), and 0, 20, 40, 200, 
or 400 µM 8918, lidamidine, or proguanil. Swimming pools were constructed from 
sterile 15 mL falcon tube caps glued inverted into Corning costar 6 well plates. Filters 
and swimming pools were incubated at 37°C for 24 hours, at which point the filters 
were placed into chilled bead beating tubes containing 1 mL 40:40:20 
methanol:acetonitrile:water and approximately 250 µL bead beating beads. Filters 
were immediately removed after sloughing the cell mat into the bead beating tube, and 
the filters were discarded. Tubes were beaten at 4°C for 8 rounds of 30 seconds on, 1 
min off. Lysates were filtered using costar Spin-X centrifuge tube filters (0.22 µM 
nylon) to remove any remaining whole cells. Lysates were then removed from the 
BSL3 and mixed 1:1 with acetonitrile containing 0.2% formic acid before being run 
on the mass spectrometer in both positive and negative ion settings. Experiments were 
performed with the assistance of Madhumitha Nandakuma, Roxanne Morris, and 
Travis Hartman. 
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Chapter 4 
8918 inhibits Phosphopantetheinyl transferase (PptT) 
Summary 
After analyzing Mtb mutants resistant to 8918 for genetic changes that could explain 
their resistance, we identified PptT as a likely candidate for the target. Two mutations 
in the same tryptophan (W) residue were identified in the screen, indicating that PptT 
may be the target and W170 may be important for 8918 binding. We therefore decided 
to investigate the role of PptT in 8918 resistance by expressing recombinant PptT and 
testing for 8918 inhibition of its it in vitro activity. We showed that in an in vitro 
enzymatic assay, 8918 could inhibit the activity of PptT in a non-competitive manner. 
The indication of non-competitive binding seemed contrary to our finding of the active 
site mutation, but we found that heterologously expressing MT PptT in WT 
background Mtb could confer high-level resistance to 8918. The co-crystal of PptT 
with 8918 indicated that 8918 did bind in a pocket near the suspected W170 residue, 
but that CoA can bind simultaneously with 8918; this may have been the cause of the 
non-competitive inhibition result from the in vitro assays. Finally, we investigated the 
changes in lipids that occurred after sublethal concentrations of 8918, and saw that 
treatment caused depletion of downstream PptT products including PDIMs, 
sulfolipids, cardiolipins, and mycolic acids.  
  
Introduction 
The production of active acyl carrier proteins is an extremely common and essential 
cellular process. Phosphopantetheinyl transferase (PptT) catalyzes the activation of 
acyl carrier proteins (ACPs) by transferring the 4’-phosphopantetheine (ppt) moiety 
from Coenzyme A (CoA) onto apo-ACPs, thereby transforming them into holo-ACPs, 
as shown in Figure 1. Holo-ACPs are active and are essential for the synthesis of 
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precursors for a number of cellular products, including mycolic acids and 
mycobactins1. Mycolic acids are significant in Mtb biology as they are essential for 
the bacteria’s ability to evade host immune cells, which plays a large role in the ability 
of the cells to remain viable and virulent2. Mycobactins are siderophores Mtb produces 
and are associated with the cell wall or secreted and can sequester iron; thus they 
represent a crucial mechanism by which Mtb can acquire iron in iron-deficient 
environments, such as within a granuloma or macrophage3,4.  
 
Figure 1: Schematic of reaction catalyzed by PptT and products of PptT 
 PptT catalyzes the conversion of apo-ACPs to holo-ACPs by transferring the 
phosphopantetheine arm of CoA onto the acyl carrier protein, releasing adenosine 3’, 
5’ bisphosphate as a product.  
  
PptT has been an attractive drug target for some time and was shown by 
Leblanc, et al. 2012 to be essential for infection in vivo; it was therefore hypothesized 
that a PptT inhibitor would work to kill Mtb during treatment5. Further, Mtb pptT is 
distinct from acyl carrier protein synthases in other bacterial species, and also distinct 
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from human equivalent enzymes. It was therefore hypothesized that an inhibitor may 
be narrow spectrum and have few if any on-target effects on mammalian cells.  
  
Results 
When PptT was identified as a potential target of 8918, we first were interested in 
investigating how PptT differs from other phosphopantetheinyl transferases, especially 
since 8918 appeared to have narrow specificity in our microbial screen. PptT in Mtb is 
distinct from other enzymes of similar function, however, in that Mtb has two 
enzymes that may catalyze the formation of holo-ACPs: PptT and acyl carrier protein 
synthase or AcpS. AcpS and PptT have distinct substrates, and AcpS is not essential 
for Mtb survival1. It is possible that even though the two enzymes have distinct 
substrates, in the absence of AcpS, PptT can phosphopantetheinylate the substrates of 
AcpS, though AcpS cannot activate PptT substrates6. We hypothesized that AcpS has 
structural similarity to other bacterial acyl carrier protein synthases, but that PptT was 
distinct, which would rationalize the narrow/mycobacteria specific activity of 8918. 
After using T-Expresso to align sequences of Mtb PptT and AcpS from a variety of 
bacterial species, we saw that AcpS from Mtb has strong structural similarities to other 
bacterial AcpS proteins, but that PptT is more distinct despite a few regions of 
similarity (Figure 2A)7,8. We also saw that PptT has closer structural alignment with 
mammalian PptT-like enzymes than it does with AcpS, though it still does not have 
significant homology with these non-bacterial PptT enzymes (Figure 2B).  Finally, we 
saw that the tryptophan 170 residue is highly conserved among mycobacteria species, 
indicating another explanation of 8918 specificity (Figure 2C). 
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Figure 2:  T-Expresso analysis of Pptases from several species (A) structural 
alignment based on sequence of Mtb AcpS and Escherichia coli AcpS, Pseudomonas 
alcaligense AcpS (P. aeruginosa gene information unavailable), Staphylococcus 
aureus AcpS, and Mtb PptT (B) Structural alignment based on sequence for Mtb PptT, 
Candida albicans PptT, and human PptT. (C) Structural alignment based on sequence 
for Mycobacteria species PptT, W170 highlighted by box. 
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Figure 2 continued 
B. 
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Figure 2 continued 
C. 
 
In vitro enzymatic examinations indicate PptT is inhibited by 8918 
With heterologous expression of MT PptT in WT Mtb conferring resistance, we 
wanted to test 8918 and PptT in vitro in an enzymatic assay to see if we could 
characterize the degree of inhibition of PptT by 8918. We collaborated with John 
Mosior and Jim Sacchettini at TAMU for these results.  
 PptT was heterologously expressed in E. coli and purified. The enzyme was 
then used in a BpsA assay, which is a frequently used assay to test the activity of 
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phosphopantetheinylating enzymes9,10. BpsA can be expressed in the apo form, and 
when it is combined with an enzyme capable of phosphopantetheinylation (such as 
PptT) and CoA as a cofactor, it can be activated into the holo form, and subsequently 
convert 2 glutamate molecules into indigoidine9. Indigoidine is colored and production 
can be observed at 590 nm, therefore the assay was set up with PptT, CoA, BpsA, and 
glutamate. Indigoidine was used as the readout of productivity of PptT. We observed 
that 8918 inhibited PptT at 5 µM, a fatal dose to Mtb in vitro, but we also observed 
that fatal doses did not fully abolish the activity of PptT, even up to 80 µM (Figure 
3A). The maximum inhibition observed was about 87% at the highest dose tested 
(Figure 3A), despite the relatively high potency indicated by the low IC50 of 2.5 µM 
(Figure 3B). This observation indicates that PptT may be a hypervulnerable target, if 
less than 100% activity may be lethal to cells. It also may indicate that PptT inhibition 
alone is not sufficient to explain the lethality observed from 8918 treatment. 
 We also observed that while Vmax was reduced, Km did not change 
significantly, increasing only from 0.601 to 0.867 over the course of 75 µM 8918. A 
reduction in Vmax and static Km generally indicate non-competitive inhibition, and 
indeed the Whitely plot of fractional velocity vs the reciprocal of inhibitor 
concentration shows that inhibition of PptT by 8918 was non-competitive (Figure 
3C). 
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Figure 3: Impact of 8918 on recombinant PptT (A) Activity of 8918 against 
heterologously expressed PptT in vitro. Uninhibited PptT activity (circles) reaches a 
Vmax of about 11.9, while 5 µM (squares), 10 µM (triangles), 20 µM (inverted solid 
triangle), 40 µM (inverted empty triangle) and 80 µM (stars) 8918 treatment inhibit 
PptT in a dose-dependent manner. Vmax and Km are shown +/- the standard error at 
each concentration of 8918 in µM. (B) Inhibition of 8918 on PptT. The IC50 was 
about 2.5 µM. (C) plot of V/V0-V +1/I for PptT and 8918. Experiment performed by 
John Mosior, TAMU. 
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Figure 3 continued 
C. 
  
Lidamidine is a weak inhibitor of PptT 
Consistent with our previous findings that lidamidine can cause similar metabolic 
changes to 8918 and is growth inhibitory at very high doses in vivo, we observed that 
lidamidine can inhibit PptT but to a lesser degree than 8918. Lidamidine similarly 
reached a max inhibition of about 88% but had an IC50 around 15 µM (Figure 4). It is 
interesting that lidamidine is not lethal to Mtb anywhere near comparable levels to 
8918, given that its IC50 is only about 6 times higher than 8918, and lidamidine 
appears to associate with the cells 10x more than 8918. It may be that lidamidine 
sticks to the membrane more than 8918, thereby appearing to have a cellular 
association, but that little accumulates truly within the cells. It may also be possible 
that intracellular segregation of lidamidine from PptT is possible, but not for 8918. 
The MIC90 of lidamidine is at least 31 times higher than the MIC of 8918. We also 
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observed that lidamidine appears to act as a non-competitive inhibitor of PptT, albeit a 
much weaker one than 8918.  
 
 
Figure 4: Inhibition of PptT by lidamidine, IC50 was 15.1 µM. Experiment 
performed by John Mosior, TAMU. 
 
The finding of non-competitive inhibition was unexpected, given that the PptT 
W170S and W170L mutants we observed were highly resistant to 8918, and this 
residue projects over the phosphopantetheine pocket of the PptT active site. The 
location of the mutation in the target implied that the resistance was a result of a 
change in the ability of 8918 to bind to the target. When we tested the W170S mutant 
in vitro we observed that the mutant PptT was in fact resistant to inhibition by 8918, 
though not completely (Figure 5). The lowest Vmax observed for the MT W170S 
mutant after 8918 exposure was 3.77 µM CoA/Hr at 80 µM, as compared to the Vmax 
for the WT after 8918 exposure which was 1.56 µM CoA/Hr at 80 µM. We also 
observed that the mutant PptT seemed to show non-competitive inhibition as well, 
with Vmax reducing during inhibition but no significant change occurring in Km. 
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Figure 5: Activity of 8918 on MT W170S PptT. Untreated Mt PptT (circles) 
compared to 5 µM (squares), 10 µM (triangles), 20 µM (inverted solid triangle), 40 
µM (inverted empty triangle) and 80 µM (stars). Vmax and Km are shown +/- the 
standard error at each concentration of 8918 in µM. Experiment performed by John 
Mosior, TAMU. 
 
Another potential explanation for the apparent non-competitive inhibition 
kinetics could be that 8918 inhibits PptT uncompetitively. In uncompetitive inhibition, 
an inhibitor binds specifically to the enzyme-substrate complex, and so could produce 
kinetics that appear non-competitive. The location of the mutated W170 residue deep 
within the PptT CoA binding pocket seems to refute this hypothesis, as the 
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hydrophobic binding pocket that holds the phosphopantetheine arm is not large 
enough for simultaneous binding of Ppt and 8918. Further, the W170 residue caps the 
end of the pocket, indicating that modulation of the binding site that interferes with 
8918 binding occurs deep within the pocket, indicating that 8918 is present fully 
inside the pocket when bound.  
 
Heterologous expression of mutant PptT in WT cells confers high level resistance to 
8918  
 Given that 8918 didn’t inhibit MT PptT as much as we anticipated, we decided 
to overexpress WT and MT pptT in WT Mtb. We hypothesized that if PptT is the 
target of 8918, overexpression of the target would result in an increase in the MIC. 
Similarly, we thought that introducing the MT PptT into WT cells could confer 
resistance to the WT, since the cells would be able to produce 8918 resistant PptT that 
could replace the inhibited PptT function. pMV261 was selected as the vector, which 
would put pptT under hsp60 control. pMV261 is often used to overexpress proteins in 
Mtb. When WT Mtb was transformed with WT pptT, however, no change in MIC was 
observed (Figure 6A). Similar results were observed with Msm. When pptT MT 
W170L in pMV261 was introduced into WT Mtb, however, an approximately 30-fold 
shift in resistance was observed. The level of resistance was the same as the original 
W170L mutant (Figure 6B). Similar results were observed in Msm, and no cross 
resistance to major antibiotics (PAS, EMB, MOXI, RIF) occurred, indicating that the 
resistance associated with the pptT W170L mutant was specific to 8918, and that the 
mutation was sufficient to cause high level resistance to 8918 even in the presence of 
WT pptT. It is possible that overexpression of pptT is toxic and therefore 
overexpression of WT pptT sufficient to cause resistance is impossible, but a small 
number of MT PptT enzymes are sufficient to confer resistance to 8918. Western 
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blotting of overexpression was inconclusive; native levels of PptT were not high 
enough to be visible on a western blot, nor were the concentrations of WT or MT PptT 
in the overexpression strain.  
 
A. 
 
B. 
 
Figure 6: Expressino of WT or MT PptT in Mtb. (A) MIC of 8918 against WT Mtb 
(black) and WT Mtb with pMV261:pptT (blue) (B) MIC of 8918 against WT Mtb 
(black), MT Mtb (W170L) and WT Mtb with pMV261:pptT:W170L 
 
Crystallization of PptT shows 8918 binds in the active site 
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We were confident that 8918 could inhibit PptT, and that mutation in PptT could 
prevent cells from dying during treatment with 8918, but we were uncertain how a 
presumed active site mutation (W170) could result in resistance if 8918 were a non-
competitive inhibitor. John Mosior (TAMU) produced the co-crystal of 8918 and PptT 
at 1.76 Å, using the protocols for PptT crystallization previously reported as 
guidelines10,11, and saw that 8918 does appear to bind in the active site of PptT 
(Figure 7A-C). The structure revealed that PptT formed a dimer with 8918 bound in 
the active site (Figure 7A). 8918 was also observed in some interstitial space between 
the two proteins, but is believed to be an artifact of high concentration of 8918 in the 
crystallization conditions (Figure 7A). It appeared that 8918 bound in a pocket with 
key interactions with K156, Y160, L171, and that W170 capped off the bottom of the 
pocket, (Figure 7B) indicating a rationalization for the resistance observed in the 
mutants.  
We observed that CoA co-crystalized in the protein (Figure 7C). CoA was not 
added during the purification, but PptT likely co-purified with CoA due to high 
affinity between PptT and CoA12. Interestingly, while the adenosine 3’, 5’ 
bisphosphate portion of CoA appeared stable in the protein crystal, the 
phosphopantetheine (ppt) arm of CoA was not able to be resolved, possibly due to a 
very low degree of electron density such that it could not be concretely placed in the 
structure, which could mean the ppt arm is mobile and not stabilized by binding. This 
suggests that 8918 binds the active site concurrently with CoA and can disrupt the 
placement of the ppt arm of CoA (Figure 7C). Published crystal structures of PptT 
bound to CoA do indicate that normally the ppt arm of CoA binds where we observed 
8918 in these crystals10,12.  
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Figure 7: Crystallographic analysis of PptT bound with 8918 
(A) The 1.76 Å model of PptT bound with CoA and 8918, as produced from the 
electron density in the PptT crystal. 8918 molecules identified are shown inside white 
boxes. Amino acids involved in water binding are shown as sticks rather than protein 
cartoon. (B) 8918 shown in the pocket with relevant stabilizing residues especially 
K156, Y160, L171, P173, and W170 at the bottom of the pocket. (C) 8918 (1) shown 
bound as well as the adenosine 3’, 5’ bisphosphate (2) region of CoA. Magnesium 
ions (green) were also identified in this pocket, likely as artifacts of the crystallization 
conditions. Structure produced by John Mosior (TAMU) 
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With the crystal structure in hand, uncompetitive inhibition of PptT by 8198 
seems unlikely, as the 8918 molecule binds tightly into the Ppt binding pocket, and 
Ppt is not present in the binding structure. While non-competitive inhibition kinetics 
are possible with inhibitors that bind the active site13, it may be possible that in this 
case non-competitive inhibition was observed despite the presence of 8918 in the 
active site because 8918 does not displace CoA, but rather can displace the relatively 
mobile phosphopantetheine arm and prevents catalysis without full displacement of 
the cofactor. As a result, inhibition would appear non-competitive because CoA 
cannot compete with 8918 for the binding pocket, since both molecules can bind 
simultaneously.  
 
Lipidomic analysis of Mtb treated with 8918 supports PptT inhibition 
With the knowledge that 8918 can bind in the active site of PptT, we wanted to 
examine what downstream effects PptT inhibition would have on lipid biosynthesis. 
Because PptT is a crucial enzyme for the activation of enzymes involved in the 
synthesis of a wide number of lipid precursors, we expected that inhibition of PptT, 
even partial inhibition as we observed in vitro, would result in far reaching depletions 
of a variety of lipid species. In collaboration with Dr. Travis Hartman in the Rhee lab, 
we used a lipidomics assay, similar to the metabolomics platform previously 
described. We examined what impact sublethal concentrations of 8918 would have on 
live Mtb over a relative short time frame of 24 hours. We observed that a number of 
lipid species directly downstream of PptT were indeed decreased in 8918-treated cells 
as compared to untreated WT Mtb (Figure 8A-B). There were a number of isoforms 
within a lipid species—these represent lipids with various acyl chain lengths or 
oxidation states within the same species. It was clear that even modest reduction of 
PptT activity can result in strong depletions of lipid species downstream of PptT.  
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Figure 8: Heatmap of lipids observed depleted in 8918 treated cells after 24 
hours. Cells were compare to untreated cells, and normalized to glucose 
monomycolates which were statistically determined to be the species with the least 
variation between untreated and treated cells. Color gradient represents decreases on a 
Log2 scale, with green representing a decrease as compared to untreated cells. This 
experiment was performed by Travis Hartman. 
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A. 
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Figure 8 continued 
B. 
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We noted that mycolic acids and phthiocerol dimycocerosates (PDIMs) were 
depleted as expected, but unexpectedly menaquinone was also significantly depleted 
in treated cells (Figure 8) 
 
Figure 9: Illustrative changes in lipid levels in Mtb grown on a filter 24 hours 
after the filter was transferred to a fluid reservoir containing 8918 (40 µM). 
Means ± SD of triplicates in 1 experiment representative of 2. p values for depletion in 
unpaired two-tailed t tests = 0.02 for mycobactin, 0.002 for PDIM, 0.02 for mycolates, 
and 0.001 for menaquinone. 
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Discussion 
Crystallization of the PptT enzyme indicated that 8918 binds to the active site within 
the pocket normally occupied by the phosphopantatheine portion of CoA, despite in 
vitro enzymatic data which indicated that 8918 was a non-competitive inhibitor, 
though this data could be a result of concurrent binding of CoA and 8918 in the active 
site. The structure of the ppt binding pocket supports the hypothesis that 8918 inhibits 
PptT by preventing catalysis of the ppt transfer onto apo-ACPs. The pocket structure 
as well as the highly conserved W170 residue that appears to be integral to the activity 
of 8918 makes a strong argument for the specificity of 8918. Because Mtb treatments 
are typically very long, antibiotics that are as narrow spectrum as possible are 
desirable. Current standard Mtb treatment typically results in profoundly disrupted gut 
microbiota, because the standard antibiotics (especially RIF) can kill a wide variety of 
normal gut flora, and the effects of the treatment related dysbiosis can be extremely 
long lasting14-16. Host microbiota have been shown to have widespread impact on the 
immune system, and some have postulated that the relatively high TB relapse rate of 
patients who have been treated for Mtb may be partially due to microbiota dysbiosis17-
18. Accelerated HIV18 and diabetes14,19 disease progression have been associated with 
microbiota dysbiosis, and both conditions are risk factors for active TB infection. 
Dysbiosis is also associated with diarrhea and discomfort which can be a contributing 
factor to patient noncompliance with MTB treatment regimes14,20. Therefore, a drug 
that only targets Mtb could have the benefit of reducing gut microbiota dysbiosis and 
its associated problems. Because PptT in Mtb is structurally dissimilar from other 
bacterial acyl carrier protein synthases, we hypothesize that a PptT inhibitor would be 
reasonably narrow spectrum, and likely would not be able to inhibit normal gut 
bacteria, thereby preventing dysbiosis.  
In addition, a drug that is only used to treat Mtb would have the benefit of not 
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generating incidental resistance. Some current TB drugs are used to treat a number of 
different infections, and if a patient is treated for a non-TB infection, but is 
concurrently and unknowingly infected with MTB they may accidentally generate 
mono-resistant Mtb, which would make their infection harder to treat if they develop 
an active TB infection in the future. Finally, the generation of our crystal structure 
bound to 8918 may facilitate simulation-driven, rational design of better PptT 
inhibitors. 
Lipidomic analysis also supported the finding that 8918 inhibited PptT, as 
downstream products of enzymes activated by PptT were found to be decreased after 
8918 treatment. Some of the depleted lipids were expected; PDIMs and mycolic acids 
require PptT activity for their synthesis. Mycolic acids are essential for Mtb membrane 
function, as they help provide structure, fluidity, and barrier to extracellular 
conditions21. Inhibition of mycolic acid synthesis is the main mechanism of action of 
INH, which is a very effective frontline Mtb drug22,23. PDIMs have been implicated in 
virulence; loss of PDIMs occurs often during laboratory passaging of cultures but is 
directly related to a loss of Mtb virulence24. Sulfolipids and cardiolipins are 
downstream products of PptT via activation of the PKS13 system as well, and 
reductions may have impacts on Mtb’s ability to manipulate the host immune system 
or regulate cell division25,26. The finding of depleted menaquinone was unexpected, 
but we believe that a reduction in menaquinone can be explained by a bottleneck in 
isochorismate and salicylate availability; mycobactin is also a downstream product of 
PptT and requires salicylate as a substrate for synthesis4,27. Mtb synthesizes 
isochorismate from salicylate, and isochorismate is a necessary substrate for 
menaquinone synthesis. We were unable to determine with confidence the identity of 
mycobactin in our lipidomic analysis, but it is possible that during PptT inhibition Mtb 
prioritizes some processes over others, and may reserve salicylate for mycobactin 
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synthesis and deprioritize menaquinone. Menaquinone is an essential electron 
transport chain electron carrier, and many reactions depend on it for shuttling 
electrons; as a result inhibitors of menaquinone synthesis have been studied or desired 
for many years28-30. We were not able to detect salicylate in our metabolomics studies 
but it may be worth pursuing later, as the actual mechanism that causes Mtb to die in 
the presence of 8918 may be directly related to the reduction in menaquinone and the 
inability of the cells to properly shuttle electrons. 
Lipidomics provided evidence of in vivo PptT inhibition, and our enzymatic 
experiments also provided strong evidence that the cidality of 8918 on Mtb was 
mediated by inhibition of PptT. It was interesting to discover that 8918 could not fully 
abolish PptT activity in vitro, and it was also unexpected that the mutant PptT enzyme 
was inhibited by 8918 to a surprising degree in vitro. While that finding may indicate 
that PptT is not the target, we observed that expression of the PptT W170 mutant 
conferred high level resistance to WT cells. This was despite the in vitro data 
indicating that mutant PptT was inhibited by 8918 to a degree that should be lethal at 
much lower concentrations than we observed in vivo. The implication is that PptT is 
being inhibited by 8918, but that there may nuances in the way that 8918 reaches the 
target in vivo. It’s possible that the mutant Mtb strain is in some way more effective at 
sequestering 8918 away from PptT than the WT, but it may also be possible that PptT 
is even more susceptible to inhibition in vivo than the in vitro results would suggest. 
We did not observe any other mutations in the W170 mutant strains that could explain 
a complementary genetic component to the W170 mutant resistance. Given PptT’s 
role in the production of membrane lipids, it is possible that the reduced efficiency of 
the uninhibited PptT mutant enzyme (Vmax 9.06 for the mutant vs 11.9 for the WT) 
may somehow slightly alter the formation of the mutant Mtb membrane that can help 
increase resistance beyond the simple active site mutation, and may provide additional 
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protection to the susceptible target.   
The finding that 8918 does not fully abolish activity of PptT at lethal 
concentrations was very interesting, as it indicates that Mtb is hypersusceptible to 
PptT inhibition. PptT may represent an even more attractive drug target than before; if 
only partial inhibition (around 37%, the max reduction in Vmax at 5) is sufficient to 
cause cell death, Mtb may be more reliant on PptT for cellular processes than 
previously thought, and it may be possible to produce a wider range of inhibitors if 
relatively low levels of inhibition can cause cell death. It may also indicate that Mtb 
death from PptT inhibition is exceptionally sensitive because of additional processes 
that occur beyond PptT inhibition. Because we observed so many mutations in another 
gene, rv2795c, that seemed to cause high-level resistance, we hypothesized that 
Rv2795c may be involved in the hypersusceptibility of Mtb to PptT inhibition. 
 
Materials and Methods 
 
Primers to express pptT in Pmv261 
For: caagcagctggcccagttccgggaacgattg (PvuII restriction) 
Rev: caagaagctttcatagcacgatcgcggtcag (HindIII restriction) 
 
Lipidomics: 
Filters were prepared with cell mats as for metabolomics, and placed on swimming 
pools containing 40 µM 8918 or lidamidine for 24 or 48 hours. Filters were removed 
from the swimming pools and placed into 13x100 mM glass screw-top vials with 5 
mL 1:2 chloroform:methanol and quickly removed. Vials were shaken overnight at 
room temperature, then spun at 2000 g for 30 min at 4° C. Supernatant was decanted 
and cells resuspended in 1:1 chloroform:methanol, vortexed vigorously, and spun at 
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2000 g for 30 min, 4° C. The wash/vortex/spin cycle was repeated with 2:1 
chloroform:methanol. Supernatants for each sample were pooled, evaporated under 
nitrogen, and resuspended in 1/10 starting volume 70:30 [v/v] hexane:isopropanol, 
0.02% formic acid [m/v], ammonium hydroxide 0.01% [m/v]. Lipidomics analysis 
performed by Travis Hartman. 
 
Purification of PptT 
E. coli BL21 cells were grown to OD580 0.6-0.8 and induced with 0.5 mM IPTG 
overnight at 15 °C. Cells were resuspended in lysis buffer (50 mM NaPO4 pH 6.5, 0.5 
M NaCl, 1 mM MgCl2, 5 mM imidazole and 25% glycerol) and lysed in a French 
press. Lysates were spun at 35000 G for 45 min and lysate passed over Ni-NTA resin. 
Resin was washed with 600-800 mL lysis buffer and eluted with elution buffer (50 
mM NaPO4 pH 6.5, 0.5 M NaCl, 1 mM MgCl2, 250 mM imidazole and 25% glycerol). 
Tobacco etch virus (TEV) 1:30 w/w ratio was added and samples dialyzed overnight 
at 4°C in 25 mM NaPO4 pH 6.5, 0.5 M NaCl, 1 mM MgCl2, 1 mM DTT, 25% 
glycerol. Protein was passed back over Ni-NTA column and concentrated on 10000 
MW Centricon. 
 
Purification of Apo-BpsA 
Protein was expressed in BL21 DE3 cells grown to OD540 0.6-0.8 and induced with 
0.5 mM IPTG overnight at 18°C, no longer than 17-18 hrs. Cells were resuspended in 
lysis buffer (50 mM Tris-HCl pH 7.9, 0.5 M NaCl, 5 mM imidazole, 12.5% glycerol) 
and French pressed. Lysate was spun down at 35000 G for 45 minutes, supernatant 
passed over Ni-NTA column, and washed with 600-800 mL lysis buffer. Protein was 
eluted with elution buffer (50 mM Tris-HCl pH 7.9, 0.5 M NaCl, 250 mM imidazole, 
12.5% glycerol). TEV was added 1:30 w/w ration and dialyzed overnight at 4°C in 50 
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mM NaPO4 pH 7.8, 1 mM DTT, 12.5% glycerol. Protein was passed over Ni-NTA 
column and concentrated on 100000 MWCO centricon.  
  
PptT-BpsA Reaction Method 
75 uL of buffer 1 (75 mM Tris-HCl pH 7.8, 15 mM MgCl2, 16 mM L-glutamine, 10 
mM ATP, 2.5 nM PptT, 0.5 mM DTT, and a 2-fold dilution series of CoA from 200-
0.09 µM ) were added to a 96 well plate. Reaction was initiated by adding 75 uL of 
buffer 2 (75 mM Tris-HCl pH 7.8, 15 mM MgCl2, 3.4 uM Apo-BpsA, and inhibitor if 
applicable) and absorbance was recorded at 590 nM.  
 
Crystallization of PptT 
PptT was incubated with excess 8918 and screened against Hampton research 
crystallization conditions. The most promising condition (100 mM bis tris propane, 
pH 6.7, 1.8 M MgSO4) was optimized by varying the pH and precipitant concentration 
using vapor diffusion (hanging drop, 5-10 uL, 50:50 protein:condition). Crystals 
formed within 6 days and generally grew to maximum size within 2 weeks. Crystals 
were cryoprotected by dipping them into mother liquor solution containing 30% 
glycerol. X-ray diffraction data was collected at 19-ID (APS Argonne National Labs) 
using a cdd ADSC Quantum 315r detector at a wavelength of 0.9253 Angstroms. The 
on-site HKL3000 package (HKL research, Inc., Charlottesville, VA) was used for data 
reduction (indexing, integration and scaling). 
 
Structure Determination and Refinement of the PptT CoA 8918 complex 
Molecular replacement using Phenix PHASER was used to phase the PptT-CoA-8918 
structure using the reported PptT structures 4QJK and 4QVH as search models 
(having removed all heteroatoms). The PptT CoA 8918 complex crystallized in the C2 
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space group, with unit cell dimensions a=134.9, b=63.4, c=79.3; Α=90, β=123.15, 
γ=90. Refinement consisted of iterative cycles of rigid body, reciprocal space, 
individual ADP, and simulated annealing using Phenix refine and manual model 
building in COOT. Final R factors were 19.90% R free, 16.24% R work, Bond Dev: 
.007, Angle Dev: .960. 
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Chapter 5 
 
Rv2795c contributes to the activity of X-B016178918 on Mycobacterium 
tuberculosis by antagonizing the activity of PptT: loss of function of Rv2795c 
contributes to a mechanism of resistance to X-B016178918 
 
Summary 
rv2795c is a gene of previously unknown function. It is highly conserved among 
mycobacteria species but has very little structural or sequence homology to proteins in 
other bacterial families. We observed that loss of function mutations or KO of rv2795c 
conferred high level resistance to 8918. We also saw that Rv2795c could convert holo-
ACP to apo-ACP, liberating phosphopantetheine in the process. We therefore 
hypothesized that during 8918 treatment, partial inhibition of PptT was not sufficient 
to cause cell death without the additional activity of Rv2795c antagonizing PptT by 
de-phosphopantetheinylating the holo-ACPs produced by PptT. We propose naming 
Rv2795c PptH for its Phosphopantetheinyl Hydrolase activity.  
 
Introduction 
As previously discussed, antimicrobial resistance may arise in response to drug 
treatment in a number of ways. While mutation of the site targeted by the 
antimicrobial agent is a common mechanism of resistance, bacteria may also become 
resistant to a compound if activity of the compound is dependent on activation or 
transport mediated by a second enzyme. We found 2 different mutations in W170 of 
PptT which were logical sources of resistance, and were confirmed to confer 
resistance. We also found 7 different mutations in rv2795c that seemed to confer high 
level resistance to 8918; this finding was replicated in 8918 resistant Msm mutants. It 
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seemed apparent that this non-essential enzyme was related to 8918 activity in some 
way. Generally, loss of function mutations are more likely than gain of function 
mutations, therefore, we suspected that the mutations observed in rv2795c were 
inactivating, especially as Rv2795c is a non-essential enzyme, and complete loss of 
function could impact the activity of 8918 without having an effect on the viability of 
the cell. With this in mind, along with the vulnerability observed in PptT as exhibited 
by cell death with relatively incomplete inhibition of PptT, we thought that Rv2795c 
may be involved in a new mechanism of resistance. We had shown by metabolomics 
that 8918 was not significantly modified in WT Mtb or the MT strain with a putative 
Rv2795c active site mutation. We know that 8918 can bind directly to the PptT active 
site. We also observed that 8918 accumulated to a similar degree in WT and 
Rv2795cH246N mutant cells- these findings together suggested that Rv2795c was not 
acting as an activating enzyme or effecting transport of 8918 into the cells. We posited 
that Rv2795c may be antagonizing PptT, such that when 8918 partially inhibits PptT, 
Rv2795c may convert the PptT product- holo-ACPs- into an unusable form.  
 Structure analysis of Rv2795c classifies it as a metallophosphoesterase that 
uses magnesium as a cofactor for catalysis: this is a class of enzymes that can carry 
out a wide variety of reactions including hydrolysis1. We hypothesized that Rv2795c 
may be carrying out a homologous reaction to an enzyme found in E. coli called Acyl 
carrier protein hydrolase (AcpH). AcpH hydrolyzes the phosphopantetheinyl arm off 
of holo-Acps, liberating free phosphopantetheine and generating Apo-Acp, as 
summarized in Figure 1. AcpH has been discovered and its mechanism characterized, 
but the actual purpose of an enzyme with a relatively futile and toxic reaction is not 
known2-4. Further, AcpH has been purified but activity in vivo has not been 
confirmed2. Rv2795c does not share significant structural homology with AcpH, but 
may carry out a similar reaction.  
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Figure 1: Reaction catalyzed by AcpH and hypothesized reaction catalyzed by 
Rv2795c.  
 
Rv2795c is a non-essential enzyme, but it is highly conserved among 
mycobacteria and does not have significant structural homology with any protein 
outside of the mycobacteria genus. This may indicate that while the enzyme is not 
essential for growth in vitro, it could have an important role in some conditions, 
including infection. It is unknown if Rv2795c is essential for Mtb infection. We 
therefore were interested in confirming; 1) if Rv2795c had a role in 8918 resistance 
and 2) what reaction Rv2795c catalyzed, and how that might fit into the biochemical 
processes of growing Mtb.  
 
Results 
Attempts to overexpress WT or MT Rv2795c had no impact on 8918 MIC 
We first determined whether overexpressing WT or MT rv2795c could confer 
resistance to 8918. We observed many putative active site mutations in Rv2795c, but 
the H246N mutation was the most common and also predicted by Phyre to have a high 
impact on catalytic activity so we selected it as our tool MT strain. We hypothesized 
that overexpressing an antagonistic enzyme could result in hypersensitivity to 8918, 
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and that overexpressing the MT gene may not result in a measurable phenotype, since 
the MT protein was most likely inactive. Because of the high degree of similarity 
between rv2795c and the Msm homologue gene msm_2647, we decided to make 
plasmids with rv2795c WT or H246N MT under the hsp60 promoter and transform 
both WT and the H246N MT Mtb and Msm.  
 When WT rv2795c was transformed into WT M. smegmatis, we observed that 
in most strains there was no change in sensitivity to 8918, but that one strain tested 
was hypersensitive (Figure 2A). The hypersensitive strain showed about a 3-fold 
change in sensitivity and was dependably hypersensitive even after freezing and 
reculturing. By contrast, the vast majority of other strains tested were similar to strain 
1 in Figure 2A, and had no change in 8918 sensitivity. We predict that overexpression 
of Rv2795c may be toxic, as overexpression of AcpH in E. coli is toxic, and while the 
promotion of Rv2795c was under hsp60 expression, the levels of protein were too low 
to be assayed by western blot, indicating that overexpression of Rv2795c may not 
have been achieved. We also observed that expressing the WT rv2795c gene in a Msm 
strain with a presumed loss of function (LOF) mutation in msm_2647 (Y97D) did not 
result in any change in sensitivity to 8918 (Figure 2B). We expected that this 
transformation would result in a strain that was more sensitive to 8918, but it may be 
possible that the gene is not being overexpressed, or that the mutation and loss of 
function of the gene is somehow dominant and the phenotype from the introduction of 
the WT gene is not observable. We believe that the toxicity of Rv2795c may have 
resulted in regulation or mutation of the promoter to protect the cells from the 
deleterious effects of overexpression of Rv2795c.   
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Figure 2: Impact of Rv2795c expression on Msm sensitivity to 8918.  
(A) Expression of WT Rv2795c in WT Msm cells resulted in one strain that was 
repeatably hypersensitive to 8918, but many strains that had no change in sensitivity. 
(B) Expression of WT rv2795c in a strain of Msm with a predicted loss of function 
(LOF) mutation (Y97D) in the rv2795c homologue Msm_2647 resulted in no change 
in sensitivity to 8918.  
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While the homology between msm_2647 and rv2795c is high, we knew that 
the results of testing in Msm may not correlate to results in Mtb. We tested the 
transformation products of the same plasmids described above in Mtb. We observed 
that when WT Rv2795c was introduced into WT Mtb there was no change in 
sensitivity to 8918 (Figure 3A) and that expressing the MT H246N rv2795c in the 
WT Mtb also did not have any impact on sensitivity to 8918. A major caveat to this 
experiment is that we are unsure if the gene was actually being overexpressed; while 
the gene was under the hsp60 promoter neither the WT nor the transformed strain 
containing the plasmid contained enough protein to be visible in western blot. Our 
antibodies for detecting Rv2795c were raised in rabbits against a synthesized peptide 
fragment of the last 20 amino acids of Rv2795c. The antibodies were able to bind to 
the peptide fragment they were raised with, as well as recombinant Rv2795c, so we 
inferred that the levels of Rv2795c in the volume of culture we were able to use were 
too low for detection. We suspect that rv2795c overexpression is toxic and that these 
strains are not actually overexpressing the protein.  
 We also transformed MT Mtb with a plasmid that encodes rv2795c with the 
H246N mutation (rv2795cH246N). This strain is highly resistant to 8918 but 
transforming with WT or MT rv2795c had no impact on sensitivity (Figure 3B).  
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A. 
 
B. 
 
Figure 3: Mtb sensitivity to 8918 when expressing WT or MT rv2795c  
(A) WT Mtb is sensitive to 8918 (black circles) but WT Mtb expressing WT rv2795c 
(blue line, black squares) on a new plasmid does not have any change in sensitivity to 
8918; WT Mtb expressing rv2795c MT H246N also does not have any change in 
sensitivity to 8918 (red line black triangles). (B) MT Mtb with mutation H246N in 
rv2795c is highly resistant to 8918 (black) but introducing the WT rv2795c (cyan line 
inverted black triangles) does not restore sensitivity. Introducing MT rv2795cH246N to 
the mutant strain also does not impact sensitivity (purple line, black diamonds).  
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  We again suspect that overexpression is toxic, as we expected that 
overexpression of WT rv2795c in either WT or MT strain would have result in 
hypersensitivity to 8918. By contrast, the presence of active Rv2795c in the WT Mtb 
would most likely be dominant, and in the WT:rv2795cH246N heterologous strains we 
would have no reason to suspect that the mutant LOF Rv2795c would be dominant, 
and these strains we would expect to have no change in sensitivity to 8918. Despite 
the fact that mutant inactive rv2795c would presumably not be toxic to cells, Rv2795c 
levels in this strain were also not high enough to be detectable by western blot.  
 
Knocking out rv2795c confers high level resistance to 8918 
With little information gained from heterologous expression of rv2795c in Mtb, we 
decided to knock out (KO) the gene in order to probe the activity of rv2795c in 
relation to 8918 activity. We expected that knocking out rv2795c would result in 
resistance to 8918, as we suspected that the rv2795c mutations we had observed in the 
resistance screen were LOF, so the KO would likely behave the same as the mutant. 
Because rv2795c is in an operon upstream of pptT with a few nucleotides of overlap, 
we wanted to be careful not to disrupt the expression of pptT when we removed 
rv2795c, as the essentiality of pptT means that any disruption of the gene would result 
in non-viable cells and the KO would be unsuccessful. The overlap of the two genes 
indicated that the translation initiation site for pptT was potentially contained within 
rv2795c, so we decided to generate 2 strains with different translation initiation sites 
for pptT.  
 For the first strain we decided to insert a Shine-Dalgarno sequence (SD3)5,6 for 
pptT at the end of the hygromycin resistance (HygR) cassette which would be 
replacing the rv2795c gene; this construct was named KO1. For the second strain we 
decided to use the predicted native translation initiation (NTI) sequence for pptT, 
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which is a short (~20 bp) segment of rv295c. We inserted a stop codon after the hyg 
insertion followed by the NTI, hopefully to avoid disruption of pptT expression. This 
construct was named KO2. We hoped that of these two options at least one would 
preserve the translation of pptT such that we would have viable cells with an rv2795c 
KO. The summary of these constructs is shown in Figure 4. 
 
 
Figure 4: Summary of KO constructs. HygR is hygromycin resistance cassette, SD3 
is Shine-Dalgarno 3, and NTI is native translation initiation.  
 
 After generating these knockouts and verifying the presence of the HygR 
cassette in the correct location by PCR and whole-genome resequencing, it appeared 
that the SD3 KO (KO1) and the NTI KO (KO2) were both resistant to 8918, but that 
KO1 was much more resistant than KO2. KO1 was about as resistant as the original 
rv2795c mutant H246N, while KO2 was only marginally more resistant than WT to 
8918, and was less resistant than the H246N mutant (Figure 5A and B). We 
hypothesized that the SD3 translation initiation site may result in a strain that is 
slightly overexpressing pptT as compared to WT, and the NTI strain may have slightly 
lower pptT expression than WT. It’s possible that the predicted NTI was not complete, 
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or that expression of pptT is in some way dependent on the expression of rv2795c.  
A. 
 
B. 
 
Figure 5: Effect of 8918 on the different knockout strains. (A) Δrv2795c with 
Shine-Dalgarno translation initiation site for pptT (KO1) (blue) is highly resistant to 
8918, comparable to the original rv2795cH246N mutation (red) and both are much more 
resistant than WT (black). (B) The Δrv2795c strain made with the predicted NTI site 
(KO2) (blue) is less resistant to 8918 than KO1 or the MT H246N (red), but is still 
much more resistant than WT (black).  
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PCR of the HygR cassette and surrounding sequence confirmed that HygR was 
present in the correct region for 12 out of 16 mutants selected for further studies. 
Whole genome resequencing was conducted on four strains, two each of KO1 and 
KO2, all of which had been confirmed by PCR. One each of the constructs contained a 
silent SNP in pptT which may have some impact on the expression of pptT; this may 
be of interest for further studies, as the level of PptT expressed in the cell may be 
dependent on the levels of Rv2795c present, and this SNP may have some effect on 
the expression of pptT. For the purpose of this study however, the other strains tested 
were found to have minimal SNPs present in other genes, and were selected as the 
representative strains for their respective constructs. The summary of the SNPs 
identified in these strains can be found in Table 1. 
 
Table 1: Summary of SNPs found in KO1 and KO2.  
 
 Position  Gene  Description AA Change  
 
SNP 
KO1 132415 rv0109 PE_PGRS1 R346G C 
608334 rv0516c anti-anti-sigma factor M69L T 
837036 rv0746 PE_PGRS9 T445A A 
3250670 rv2931 ppsA 
frameshift at 
N1287 C 
3381807 rv3021c PPE47 (pseudogene) frameshift at A5 G 
KO2 132415 rv0109 PE_PGRS1 R346G C 
608334 rv0516c anti-anti-sigma factor M69L T 
837036 rv0746 PE_PGRS9 T445A A 
3249676 rv2931 ppsA frameshift at E958 A 
3381807 rv3021c PPE47 (pseudogene) frameshift at A5 G 
  
Several of the mutations observed were identical between strains, indicating that these 
mutations may have been present in the parent strain used to generate the KOs. These 
mutations are not hypothesized to have any impact on 8918 activity, though the ppsA 
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mutations may be relevant. PpsA is involved with PDIM synthesis, and a frameshift 
mutations is most likely loss of function. PDIMs are important for Mtb virulence, but 
are non-essential in vitro and mutate rapidly during culture passaging7.  
As knocking out rv2795c did confer resistance to 8918, next we wanted to see 
the effect of complementing the Δrv2795c strain with the WT rv2795c gene to 
determine if sensitivity to 8918 could be restored. We also wanted to test which of the 
2 KO constructs and complement combination could restore 8918 sensitivity closest to 
WT levels. Our hypothesis was that complementing the KO would restore the activity 
of 8918, but due to our previous failure to overexpress rv2795c we were concerned 
that overexpression could be toxic. After initial attempts to complement using Ptb21 
and Ptb38 promoters on rv2795c resulted in very low transformation efficiency and 
strains that did not appear to have any change in 8918 MIC, we decided to try a panel 
of promoters for rv2795c. We predicted that with a variety of promoter strengths we 
would be able to get some mutants that were expressing a level of rv2795c that would 
not be incompatible with viability. 
Table 2 summarizes the strength of a variety of promoters tested with rv2795c 
expression. The promoters were tested by the amount of luciferase expression they 
induced when placed in front of the luxAB gene, as measured by the amount of 
fluorescence generated by LuxAB. PTB-21, PTB-38 and P16 were not tested in this 
assay, though are predicted to be as strong or stronger than P200.  
 
 
 
Table 2: Summary of promoter strengths as measured by luciferase fluorescence. 
 P200 P766-
10A 
P200-
7A 
P200-
33T 
P200-
35A 
pTB pTB P16 
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21 38 
LuxAB 
(RFU) 
28991 13492 10471 1094 381 Not 
tested 
Not 
tested 
Not 
tested 
 
All promoters and luciferase measurements were generated and performed by the 
Schnappinger lab.  
 
We observed that in general stronger promoters resulted in very low 
transformation efficiency, indicating that the expression may have been toxic and 
colonies may not have been viable. The transformation efficiency was low enough to 
be within the margin of natural kanamycin frequency of resistance. Colonies from 
strong promoter complements tended to show no sensitivity to 8918 (Figure 6A-C). 
This may be a result of mutation in the promoter impacting rv2795c expression, as we 
hypothesized was the reason for previous (failed) rv2795c overexpression attempts, 
though western blots could not detect Rv2795c to confirm expression levels. These 
strains also may not have the complementation plasmids and just be kanamycin 
resistant. If the expression of rv2795c is toxic at the levels these promoters generate, 
then the colonies that grew may not have the plasmid. For each strain and promoter, 2 
candidates were chosen and tested for the MIC to 8918, and in all cases the 2 
candidates had equivalent MICs.  
In strains that showed sensitivity to 8918 when complemented with WT 
rv2795c and not MT, P766-10A in the KO1 strain was selected as the promoter most 
likely to result in expression of rv2795c closest to WT, based on 8918 MIC90  (Figure 
6F). Interestingly, we observed that the KO2 background complements almost 
universally resulted in hypersensitivity to 8918 as compared to the WT, which has an 
MIC90 around 3 µM (Figures 6 A, B, D, E, F). We hypothesize that in normal cell 
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metabolism, pptT and rv2795c exist in balance, and when PptT is inhibited by 8918 
the MIC90 is around 3 µM. By contrast, the KO2 strains where pptT is under the 
predicted (but possibly not accurate) native translation initiation site, pptT is being 
functionally underexpressed as compared to WT, and therefore most of the promoters 
are too strong and rv2795c is being functionally overexpressed, even if protein levels 
are quantitatively less than in WT. These strains may be of future interest in lieu of a 
successful rv2795c overexpression strain, as the balance between PptT and Rv2795c 
seems to have been pushed toward Rv2795c. As expected, when knockouts were 
complemented with mutant H246N rv2795c, sensitivity was not restored in any strains 
(Figure 6F). This confirms that resistance mutations in rv2795c are LOF. All strains 
were tested against INH, RIF, PAS, and EMB, but none had altered susceptibility to 
these drugs, indicating that the changes in MIC to 8918 as a result of the genetic 
manipulation were specific.  
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Figure 6: MIC90 from complementation of rv2795c KO under the control of 
promoters of different strengths. KO2 (native translation initiation pptT 
background) with rv2795c (teal circles), KO2 with rv2795cH246N (blue triangles), KO1 
(Shine-Dalgarno pptT initiation) with rv2795c WT (red squares) and KO1 with 
rv2795cH246N (orange inverted triangles).  
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The results from the knockout and complement of rv2795c confirmed that 
while rv2795c is non-essential, the loss of the gene results in high level and specific 
resistance to 8918, implicating loss of function of rv2795c as a mechanism of 
resistance to 8918. We learned that rv2795c is involved in 8918 resistance, but 
because rv2795c was uncharacterized we lacked understanding of what reaction 
Rv2795c carried out in the cell, and how this related to PptT inhibition.  
We next wanted to determine what reaction Rv2795c catalyzes, and decided to 
try to heterologously express and purify Rv2795c and carry out enzymatic reactions to 
probe its function. We knew from metabolomics studies that Rv2795c was not likely 
to be an activating enzyme, as no major conversion products were observed in WT but 
not MT Mtb. Additionally, we did not think Rv2795c was related to transport of 8918, 
as MT and WT strains both appeared to contain similar amounts of 8918 when 
examined during metabolomics experiments. Rv2795c is classified as a 
metallophosphoesterase, which means that it likely uses a metal as a cofactor and 
could carry out a number of reactions including hydrolysis, phosphorylation, 
dephosphorylation, or esterification. Amino acid analysis of the putative active site 
using Phyre8,9 indicated that Rv2795c likely used magnesium as a metallic cofactor.  
When considering possible explanations for how loss of function could result in 
resistance that wasn’t derived from structural modification or export, we hypothesized 
that Rv2795c may be antagonizing PptT. In this case, loss of function of an enzyme 
that is antagonistic to the target could theoretically result in resistance to a drug. We 
hypothesized that Rv2795c may be acting as a phosphopantetheinyl hydrolase, and 
may dephosphopantetheinylate holo-acps and convert them back into apo-ACPs 
(Figure 7). We know that magnesium can often be used as a cofactor for hydrolysis 
reactions10-12.  We also know E. coli has an enzyme named named acyl carrier 
hydrolase, AcpH, which uses magnesium and performs hydrolysis2. While Rv2795c 
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does not have significant structural homology to AcpH, they may still be functionally 
homologous. The existence of AcpH has been confirmed from in vitro purifications 
but the activity has never been demonstrated in vivo, and the presence of a futile cycle 
that is antagonistic to an essential process has been described as an enigma2.  
 
 
Figure 7: Summary of putative reaction carried out by Rv2795c. Rv2795c may be 
able to hydrolyze the phosphopantetheinyl group from holo-ACPs and generate apo-
ACP and 4’ phosphopantetheine in the process.  
 
We attempted to express Rv2795c in E. coli, and found that expression was 
challenging, largely due to problems with solubility and toxicity. The inability of E. 
coli to express Rv2795c supported the hypothesis that previous attempts to 
overexpress in Mtb failed because overexpression of the protein is toxic. We also 
discovered that the protein was extremely insoluble. The solubility was largely 
improved by terminating the protein at amino acid 304, and deleting the last 20 amino 
acids (Rv2795c304T). We also determined that only BL21 AI strains would express the 
protein, though yields were still low as compared to non-toxic proteins. BL21 AI E. 
coli differ from other expression strains in that the T7 polymerase is under arabBAD 
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control, and induction is obtained through addition of arabinose instead of IPTG13. 
This strain therefore results in less leaky expression of any gene on a T7 plasmid. Our 
first plasmid (generated by John Mosior at TAMU) contained rv2795c in pMCSG9 
with ampicillin resistance. We observed that protein expression decreased 
substantially in cultures grown from frozen stock; we determined that pet28 
(kanamycin resistance) induced much higher expression of Rv2795c than pMCSG9, 
and that highest protein yields were obtained from freshly transformed cells rather 
than frozen stocks.  
Eventually, we were able to obtain pure His-tagged Rv2795c304T using a Ni-
NTA agarose column, as confirmed by MS of the excised gel bands (Figure 8). The 
truncated protein is about 34 kDa, but we observed several bands around 60-70 KDa. 
When the bands were excised and tested by MS, one was found to be ArnA, which is 
an arabinose related membrane protein, and may be expressed as a result of arabinose 
induction, though we are unsure why it would co-purify with Rv2795c304T. The other 
band was found to be GroL, a folding cofactor, which may be associated with 
Rv2795c as a result of instability or toxicity. Finally, a dimer of Rv2795c304T was also 
identified in the region.  
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Figure 8: Gel image of recombinant Rv2795c (~34 KDa) 
 
After numerous unsuccessful attempts to purify MT H246N Rv2795c, we 
hypothesized that the mutant protein may be too unstable to purify with similar 
methods used for the WT. We observed that while some stabilizing protein (GroL) 
copurified with WT Rv2795c, Rv2795c was the majority species present. By 
comparison, attempts to purify MT Rv2795c from the same E. coli strain and the same 
plasmid as the WT Rv2795c resulted in large amounts of SlyD and GroL, both of 
which are stabilizing/folding factors, but amounts of Rv2795cH246N were negligible 
and only detectable by western blot. By contrast, induction and purification of BL21 
AI cells alone with the same protocol did not produce these proteins, and we 
concluded that the MT Rv2795c may be very unstable.  
With the purified Rv2795c enzyme in hand, we wanted to test its activity 
against an acyl carrier protein. In vivo AcpM (acyl carrier protein meromycolate) is a 
native substrate of PptT, and is an enzyme that produces a precursor to mycolic 
acids14. We received the acpM expression plasmid as a gift from Mikael Blaise and 
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were able to purify the protein as a combination of holo and apo protein. Holo-AcpM 
is about 12.5 kDa, and when phosphopantetheine is removed in the conversion to apo-
AcpM the protein loses about 0.5 kDa. We observed that when AcpM and Rv2795c 
were combined there was a time-dependent decrease in the amount of holo-AcpM, and 
a time-dependent increase in the amount of apo-AcpM as observed by gel shift and 
confirmed by MS of the gel bands (Figure 9). In the same time frame no spontaneous 
conversion of holo to apo-AcpM was observed (not shown). AcpM can dimerize, and 
the dimer is faintly present in the gel at about 25 kDa, as confirmed by western blot 
(anti-His antibodies) and gel excision/MS.  
 
Figure 9: Conversion of holo-AcpM (~14 KDa) to apo-AcpM (~12KDa). Shown as 
a shift in MW over time (hrs) after addition of Rv2795c.  
 
Upon MS analysis of the small molecules generated by the enzymatic reaction, 
we observed the appearance of ppt in the reaction mixtures, while AcpM or Rv2795c 
alone did not release ppt over time (Figure 10). The addition of 10 µM 8918 had no 
impact on this reaction. We also observed that over time the ppt seemed to degrade, 
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and tests into what degradation products form are currently underway.  
 
   
 
Figure 10: Phosphopantetheine identified in the small molecule fraction of the 
reactions containing holo-AcpM alone, Rv2795c alone, or holo-AcpM and 
Rv2795c together over time (hours). The asterisk indicates statistical significance 
between the reactions and Rv2795c at T 0.1, which was the control sample with the 
highest amounts of ppt detected. Student’s T test and p < 0.002 for all reactions.  
 
Discussion 
The activity of Rv2795c appears to be integral to the susceptibility of Mtb to 8918. It 
is possible that a better inhibitor of PptT would not additionally require the activity of 
Rv2795c to be lethal, but the combination of PptT’s crucial cellular role and the 
presence of active Rv2795c in vivo results in Mtb being extra susceptible to PptT 
inhibition, and incapable of surviving even modest reductions in PptT activity. To our 
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knowledge, this mechanism of resistance has not been observed previously.  
 Since we have shown that Rv2795c can act as a phosphopantetheinyl 
hydrolase, we propose naming it PptH. While the function is homologous to AcpH, we 
think the structural differences and relationship with PptT justify the different name. 
We have little understanding of what purpose PptH serves in vivo. PptT or AcpS have 
been shown to be essential for cell growth, in Mtb or other species. Why then, would 
Mtb also express an enzyme that essentially makes it hypersusceptible to any 
reduction in the activity of PptT? Their presence in the same operon indicates that 
their expression may be linked in some way, but we have no knowledge of how they 
may be linked or regulated, or if they are definitely in an operon and expressed 
together. pptH was identified in a broad scale search of regulatory factor binding sites 
using ChIP-Seq, and appeared to be  associated with the transcription factor Rv0767c, 
though the p-value was >0.3 indicating that the relationship was not statistically 
relevant15. In a search of proteomics data sets publicly available, Rv2795c was not 
identified. It may be that the native protein levels of PptH are very low, and (or, 
alternatively) it is degraded in lysates. Our inability to detect PptH  in a western blot 
may indicate that the native levels are very low. 
To attempt to identify if PptH may be conditionally essential, we conducted a 
search of several data sets including Tn-Seq and microarray. One technique which was 
of interest to us was TraSH, transposon site hybridization, which was described in a 
paper specifically looking for genes in Mtb that limited growth in minimal media 
when mutated16. Rv2795c was not identified as a conditionally essential gene for 
growth in minimal media in the Sassetti study, although they stipulated that “genes for 
which the intensity fro the rich medium pool did not exceed two-times the background 
were omitted16.” If PptH is nearly as active as AcpH, levels of native expression may 
be extremely low, as higher levels may be very toxic to the cell, and detection may be 
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challenging to detect above background. We know that native protein levels appear 
too low to detect by western blot.  
In another paper, Talaat et al. used microarray to investigate the transcription 
profile of genes expressed on day 7, 14, and 21 in the lungs of SCID (severe combined 
immuno-deficient) or BALB/c mice as well as media at the same time points16. They 
published an extensive data set of their results, which included both rv2795c and pptT. 
The results were published as a ratio of cDNA/gDNA, as better results were obtained 
when cDNA levels were normalized to the concentration of genetic DNA observed. 
The summary of their findings are shown below in Table 3. 
 
Table 3: summary of ratios of cDNA/gDNA for rv2795c and pptT identified by 
Talaat, et al16. Shown ± the standard deviation, n=6-8 hybridizations. 
Condition  Day 7 Day 14 Day 21 Day 28 
BALB/c 
infection 
pptT 
pptH 
2.03 ± 0.81 
4.30 ± 1.79 
3.73 ± 3.93 
6.14 ± 5.00 
1.70 ± 1.16 
1.55 ± 0.56 
4.01 ± 0.56 
3.94 ± 0.85 
SCID  
infection 
pptT 
pptH 
1.00 ± 0.41 
0.69 ± 0.21 
2.53 ± 1.18 
3.23 ± 2.06 
3.67 ± 2.42 
4.62 ± 2.55 
8.02 ± 7.89 
4.89 ± 3.04 
7H9 broth pptT 
pptH 
17.55 ± 15.57 
6.51 ± 2.99 
5.16 ± 2.18 
4.19 ± 1.17 
12.73 ± 3.50 
4.10 ± 1.26 
5.29 ± 4.84 
3.54 ± 1.77 
 In this data, generally the SD for the DNA levels is high, which makes 
determination difficult. This high variance may again be a factor of pptH levels within 
the cell being relatively low, which would result in challenges identifying it over 
background. With that caveat in mind, a general trend can be seen that pptH levels 
seem to be higher when Mtb is actively replicating, such as in 7H9 broth.  One 
interesting finding is that on day 7, pptH from Mtb in SCID infected mice appears 
relatively low, while the BALB/c Mtb from the same timepoint seems to be higher. 
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This may indicate that the host immune system/stress may have some role in pptH 
expression. The late stage infection (day 28) in BALB/c similarly appears to have 
increased pptH expression compared to other conditions, though the authors did not 
identify pptH  as a gene with significant change in expression only during growth in 
BALB/c mice, or 7H9 broth. These results may be interesting to follow up more 
specifically with qRT-PCR in different stress conditions to determine if they can be 
replicated and under which conditions.  
 Another paper used a GeneChip system to identify the signal intensity of 
mRNA in log phase as well as during the transition to stationary phase18. They found 
that pptH was not significantly upregulated during the transition to stationary phase, 
though it appears that both pptT and acpM were downregulated during the transition, 
as would be expected.  
 Finally, from Tn-seq experiments conducted within our lab, Ruslana Bryk 
observed within her data set that after exposure to acid (pH 5.5) and NO stress (0.5 
mM) that both pptT and pptH are downregulated as compared to unstressed cells. The 
summary of her findings can be found in Table 4.  
 
Table 4: Summary of Log2 changes in mRNA levels observed by Ruslana Bryk in 
cells exposed to acid and nitrite stress, vs unstressed cells. 
 
Log2 fold change vs. d0 
P-value 
Corrected for multiple testing 
 
d00 d05 d10 d20 d00 d05 d10 d20 
pptT 0 -0.92 -1.24 -1.37 1.000 0.007 0.001 0.000 
pptH 0 -0.15 0.20 0.13 1.000 0.331 0.176 0.353 
 
From this experiment it seems that pptT expression is reduced after exposure to 
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conditions that would likely result in the cells entering a non-replicating state. The 
corresponding changes to pptH levels are less pronounced, and not significantly 
changed. It is possible that changes may occur at an earlier time point than day 5 of 
exposure, though it appears that expression of pptH is not necessary for the survival in 
these conditions at these time points, and it appears to be downregulated during stress 
responses, usually around 2 fold17. In another Tn-Seq experiment conducted in our lab 
by Kohta Saito, Thulasi Warrier, and Jianjie Mi, they observed that pptH had a 1.67 
Log2 reduction in liquid vs agar plates, with an adjusted p value of 0.18. This is a 
lower p value than was observed in many other data sets investigated, and may 
indicate that pptH is important in solid colonies or biofilm survival. The fold changes 
in these data sets are not large, but it is possible that if PptH is exceptionally active, 
that a 2 fold reduction in expression could have significant effects within the cell. 
Additionally, low expression levels may make detection of pptH mRNA challenging 
or less accurate. We are interested in pursuing the protein expression levels of pptH in 
more detail, and hope that the new library of pptH mutants and complements may 
facilitate this process.  
From the above experiments and publications, it seems that pptH is generally 
not essential, and that in many conditions the gene expression levels do not seem to 
change significantly in a way that would indicate conditional essentiality, though it 
also seems it is poorly characterized. It seems strange then, that Mycobacteria would 
carry it as a conserved gene, especially as its function appears to be toxic if 
unchecked. We observed that the population rate of mutation appears to be about 1 in 
106, and if the gene were truly non-essential it seems as though it would not be 
conserved among Mycobacteria species. It is also interesting that pptH is highly 
conserved in M. leprae. This is notable because M. leprae has undergone extensive 
genomic reduction, and only has around 1600 genes19,20; as a result the genome now 
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contains very few nonessential genes, and the organism requires a host for replication. 
pptH is predicted to be nonessential in all Mycobacteria species, and in our study with 
Mtb we confirmed that pptH was not required for growth in vitro, but it is possible 
that pptH is essential or beneficial to the bacteria in some conditions, perhaps during 
infection from host stresses, or at very short time points after stress exposure. It seems 
that the enzyme would not be present nor so highly conserved among mycobacteria if 
it did not have some benefit, especially in M. leprae, given the disadvantages of 
antagonizing PptT seem to outweigh the benefits of PptH activity. 
 If PptH is essential in some conditions, the hypothetical utility for the cell may 
be related to CoA metabolism. It has been shown that CoA may be used as a post 
translational modification for proteins during stress responses20. PptH may exist as a 
mechanism for the cells to regenerate CoA during stress exposure, and may be 
important for the cells to survive certain stress responses, including the transition from 
replicating to non-replicating states during stress or unfavorable conditions. Mtb is a 
very successful pathogen partially because of its ability to become quiescent and 
dormant rapidly, and for long periods of time, and it is possible that PptH is involved 
with some aspects of the regulations of this state. It seems logical that PptT’s crucial 
role in cell growth and membrane production might need to be tempered during stress 
to preserve resources and energy if cell growth is not a priority. If this is the case, and 
if a PptH inhibitor could be produced along with a more potent PptT inhibitor than 
8918, the two drugs could be administered simultaneously and may inhibit both 
replicating and non-replicating populations of Mtb. This would require the 
development of a PptT inhibitor that is not dependent on the antagonizing effect of 
PptH, as 8918 is. Studies to identify any conditions in which PptH is essential are 
currently underway, as in our in vitro studies PptH is nonessential, but the high degree 
of conservation among mycobacterial species suggests that it may have some 
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conditions in which it is essential. Understanding more about the biology of PptH may 
reveal weaknesses in the ability of Mtb to survive harsh conditions within the host. 
Additionally, we may discover that pptH mutations cannot confer resistance to 8918 
during in vivo infection if the gene is conditionally essential during infection, which 
would make a PptT inhibitor more effective.  
 Knowing more about PptH could also facilitate the discovery of an activator. A 
PptH activator could potentially be mycobactericidal alone, but would likely be 
synergistic with a PptT inhibitor. It could effectively lower the required dose of a drug 
and would almost certainly be extremely narrow spectrum, given the lack of structural 
homology to other enzymes. The rate of resistance would be relatively high for an 
antimicrobial, but INH and EMB for instance have rates of resistance around 10-5. A 
high rate of resistance is less of a challenge to overcome in a multidrug therapy, as the 
combined rates of resistance become low enough for resistance to be very unlikely. A 
PptH modulating drug could also be effective against M. leprae. While infection 
caused by M. leprae is not as large a threat to global health as TB, new drugs would 
certainly be welcome, as no new drugs for M. leprae have been introduced in at least 
30 years22.  
 It seems clear that PptH must be carefully regulated in Mtb, as many of our 
experiments seemed to indicate that overexpression of PptH is toxic, and the reaction 
it catalyzes logically could be devastating for the cell if unchecked. We therefore are 
interested in studying how PptH expression is regulated, and how the regulation 
between PptH and PptT may be related. We also are interested in discovering if pptH 
has any conditions in which it is essential, as an explanation for what benefit Mtb may 
gain from having the gene.   
 
Materials and Methods 
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Generation of rv2795c KO 
Plasmids containing the hyg cassette and recombination regions including SD3 or NTI 
(SDN) for pptT were ordered from GenScript in pUC57. Plasmids contain the hyg 
cassette followed by the SD3 translation initiation site (KO1) or 24 nucleotides of the 
end of rv2795c for KO2. pptT was included in the plasmid as the recombination 
sequence so that recombination would be less likely to disrupt the expression of pptT. 
Protocol was adapted from the Dirk Schnappinger lab protocol via Caroline Trujillo. 
The pUC57 plasmids were resuspended in 10 mM Tris pH 8.0 to 100 ng/µL, and 
tested for concentration using nanodrop. Next the plasmid was digested using PmeI 
restriction enzyme following the NEB protocol for the PmeI restriction enzyme, and 
using 1 µg of the pUC57 plasmid. The reaction was incubated 1 hour at 37 °C, at 
which point another µL of PmeI was added, and incubated another 2 hours at 37 °C. 5 
µL of the reaction mix was run on a 1% agarose gel to confirm digestion (~2.3 Kb 
fragment) and then gel purified using a Qiagen PCR purification kit and eluted with 30 
µL elution buffer.  
For recombination to occur we used a strain of H37Rv containing the RecET-
MA plasmid, (kanamycin resistant) given to us by the Schnappinger lab. The stock 
was thawed and grown in 7H9 with 0.2% tyloxapol, 10% Middlebrook OADC, and 25 
µM Kanamycin (kan). The cells were grown to OD580 1 and then diluted 1:25 and 
regrown to OD580 1. Once the cultures were ready isovaleronitrile was added to 1 µM 
and the cells were incubated for 8 hours at 37 °C. Then glycine was added to 0.2 M 
and incubated overnight at 37 °C. 
50 mL of cells were then used to prepare competent cells by pelleting at 4000 
RPM for 10 minutes at room temperature. They were then respuspended in half the 
starting volume of 10% glycerol and repelleted at 4000 RPM for 15 minutes. This 
procedure was repeated twice more until the cells were resuspended in 2.5 mL of 10% 
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glycerol. 400 µL of competent cells were used per transformation. 
1 µg of the digested fragment was added to each electroporation cuvette 
containing cells. The cuvettes were gently mixed and incubated for 10 minutes at 
room temperature. The cuvettes were then electroporated at 2.5 kV, 1000 Ω, 25 µF. 
Immediately after electroporation 600 µL of prewarmed 7H9 complete was added to 
the cuvettes and the cuvettes were mixed gently. The transformation cuvettes were 
incubated for 24 hours at 37 °C, then plated onto 7H10 plates containing OADC and 
50 µg hygromycin (Hyg).  
When colonies were observed, 9 candidates from each of KO1 and KO2 were 
grown in 24 well plates, with the wells containing 7H9 and 50 µg Hyg. When cultures 
were about OD580 1 they were outgrown again in 20 mL 7H9 and 50 µg Hyg for DNA 
purification and PCR confirmation. They were also streaked onto 7H10 plates 
containing 10% sucrose to cure the Rec-ET-MA plasmid. When colonies were grown 
on the plates they were picked and grown in 7H9 containing 50 µg Hyg, and were at 
this point considered ready for experimental use after confirmation of the correct 
HygR insertion.  
 
Generation of Complements:  
Complement vectors were generated using the gateway system19,20, and the promoter 
donor plasmids used were generously given to us by the Schnappinger lab. 
Complement vectors once completed with the proper promoter and Rv2795c WT or 
MT were transformed into competent KO1 or KO2 strains, which were made 
competent and transformed using the same protocol described above for knockout 
cells. The transformed cells were plated on 7H11 plates with 25 µM Kan, all 
complementation vectors carried Kan resistance. Candidate colonies were then picked 
and regrown in 7H9 with 25 µM Kan to confirm resistance, and MIC against 8918 and 
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several antibiotics were tested.  
 
Purification of AcpM 
Protein was expressed in E. coli BL21 C41 cells. Cells were grown at 37°C until 
OD580 reached 0.6-0.7, at which point they were induced with 1 mM IPTG and grown 
overnight at 15°C. Cells were spun down at 3993xg for 10 minutes and the pellet was 
resuspended in lysis buffer (50 mM Tris pH 8.0, 0.4 M NaCl, 5 mM 2-
mercaptoethanol (B-me), 20 mM imidazole), then lysed with emulsaflex. Lysates were 
spun down 45 minutes at 300000 G. Supernatants were incubated on nickel beads for 
1 hr and then put in a column for gravity washing, and washed with 600 mL lysis 
buffer, and then with 600 mL wash buffer (50 mM Tris pH 8.0, 1 M NaCl, 5 mM B-
me, 20 mM imidazole) followed by elution with 5 mL 50 mM Tris pH 8, 0.2 M NaCl, 
5 mM B-me, 250 mM imidazole. Eluted protein was incubated with 0.5 M DTT 
overnight at 37 °C, dialyzed in 50 mM Tris pH 8 3x and concentrated on 10,000 MW 
Centricon.   
 
Purification of Rv2795c 
Truncated Rv2795c was cloned removing nucleotides coding for amino acids after 
number 304 at the C terminus. Protein was expressed in E. coli Bl21 AI cells grown to 
OD580 0.6-0.7 and induced with 0.1% arabinose, and cultured overnight at 15°C. Cells 
were resuspended in lysis buffer (50 mM NaPO4 pH 7.8, 0.5 M NaCl, 1 mM MgCl2, 
20 mM imidazole and 15% glycerol) and lysed by emulsiflex. Lysate was spun at 
35000 G for 45 minutes and supernatant incubated on nickel beads for 1 hr. Cells were 
washed with 1 L lysis buffer, then 30 mL of lysis buffer containing 40 mM imidazole 
and 5 mM ATP, then 500 mL lysis buffer, 30 mL lysis with 40 mM imidazole and 5 
mM ATP, then 500 mL lysis buffer. Protein was eluted with 10 mL 50 mM NaPO4 pH 
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7.8, 0.5 M NaCl, 1 mM MgCl2, 250 mM imidazole and 15% glycerol, then dialyzed 
against 50 mM NaPO4 pH 7.8, 0.25 M NaCl, 1 mM MgCl2, 15% glycerol.  
  
AcpM and Rv2795c Reaction 
Rv2795c  (5 µM) and AcpM (10 µM) were combined with 75 mM Tris pH 8, and 15 
mM MgCl2. Reaction was spun with 10000 MWCO centrifuge filter to stop reaction 
for MS analysis or boiled in SDS-PAGE loading dye at 80°C for 10 minutes before 
protein gel analysis. Reaction mix was analyzed by SDS-PAGE on a 15% acrylamide 
stacking gel.  
 
rv2795c overexpression plasmid constructs/primers 
Forward: CAAGCAGCTGTCGTTAGGGTGGTAAGTCGTG (PvuII) 
Reverse: CTTGAAGCTTCACCGACGCCAGCGTGCCTA (HindIII) 
 
Primers for confirming correct placement of HygR cassette 
Forward: caagcagctgtagcagttgggctaggttggc 
Reverse (hyg back): agcggacctctattcacagggtac 
 
Forward (hyg out): gaggaactggcgcagttcctctgg 
Reverse: cttgaagcttcaccgacgccaccagcgtgccta 
 
Primers for generating donor plasmids for complements:  
rv2795c-SD3-
atTB2 
GGGGACAGCTTTCTTGTACAAAGTGGAGGCG
GTATCTCCGTGACCTGGAAAGGATCGGGGCA
GGAGACCG 
rv2795c-SDN- GGGGACAGCTTTCTTGTACAAAGTGGTAGGG
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atTB2 TGGTAAGTCGTGACCTGGAAAGGATC 
 
rv2795c-atTB3 
 
GGGGACAACTTTGTATAATAAAGTTGTCATC
GAGACTGCCGTTGCCGCAATCGTTCCCG 
 
Recombinant truncated (301-324) rv2795c for pet28: 
For: caagcatatggtgacctggaaaggatcggggc (NdeI restriction) 
Rev: gcaactcgagtcacgtgatcacgaagtac (XhoI restriction) 
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Chapter 6 
PptT and PptH activity together explain the sensitivity of Mtb to 8918, and 
represent a new mechanism of resistance by which partial inhibition of the target 
(PptT) is lethal but loss of function of an antagonistic enzyme (PptH) can confer 
high level of resistance to a drug-like compound 
 
Conclusion 
We found that a small, antimycobacterial compound−8918−could bind to the active 
site of the essential enzyme PptT. PptT uses CoA as a cofactor, and 8918 appears to 
bind in the portion of the active site that is normally occupied by the ppt portion of the 
CoA molecule. Because the ppt portion of CoA is the moiety that is transferred to 
activate other enzymes, 8918’s ability to destabilize this region likely is the 
mechanism by which catalysis speed is reduced. The generation of the crystal structure 
showed that 8918 and CoA can bind concurrently, and also indicated that there is a 
small region of the ppt binding pocket of PptT that is not being occupied by the acyl 
chain of 8918. These finding may help us use rational drug design to develop better 
inhibitors of PptT: perhaps larger molecules that can also displace CoA with stronger 
affinity for the pocket. 8918 is also rapidly metabolized in vivo, and the crystal 
structure with binding information may help us predict modifications which may 
reduce metabolism, or develop a new family of molecules entirely.  
 We also confirmed that inhibition of PptT was sufficient to cause cell death at 
relatively low concentrations, and that mutation of the W170 residue could confer 
high-level resistance to 8918, likely due to its proximity to the ppt binding pocket on 
PptT. We were surprised to find that the W170 PptT mutant was still inhibited by 
8918, to a degree that does not seem to fully explain the resistance the mutation can 
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confer in vivo. It would be interesting to find out what happens if W170 in PptT is 
mutated at the same time that pptH is knocked out. Maybe metabolomics or lipidomics 
analysis of the double mutants could provide insights into how the cells function with 
no PptH but also reduced PptT activity. A conditional knock down strain with ATC 
regulated PptT and pptH knocked out may be a more controlled way to investigate this 
relationship, but could have a similar phenotype to the W170/ΔpptH strain. We also 
saw that 8918 could suppress Mtb growth in models of Mtb infection in mice, despite 
the fact that 8918 is rapidly metabolized in mice and blood concentrations decrease 
rapidly. A modified compound with a lower degree of metabolism might be extremely 
potent in an in vivo model of infection. 
Sublethal concentrations of 8918 caused significant decreases in metabolites 
and lipids associated with enzymes that are activated by PptT. We can infer that at 
lethal concentrations the reduction of lipids would be much greater and could result in 
the death of the cell. We also observed that because PptT is involved in the activation 
of a wide variety of enzymes, that inhibition resulted in significant decreases in a very 
wide spectrum of products, many expected−sulfolipids, cardiolipins, mycolic acids, 
and PDIMs−and one unexpected−menaquinone. The finding of menaquinone was 
interesting as Mtb is especially dependent on menaquinone for electron shuttling1-3. 
PDIMs are important for virulence but are non-essential in vitro and reduction of 
PDIM synthesis could not explain the lethality of 8918. Similarly, cardiolipins and 
sulfolipids may have important roles in vivo, but are not essential for in vitro growth, 
and could not explain the lethality. Mycolic acids, including AcpM, are essential for 
growth, but menaquinone is a crucial bottleneck for metabolism and lethality of 8918 
exposure could plausibly be caused by a depleation of menaquinone. We are interested 
in further investigating the relationship between menaquinone and mycobactin 
biosynthesis, as our hypothesis for the depletion of menaquinone hinges on 
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isochorismate shunting for mycobactin synthesis. We were unable to confirm the 
identity of mycobactin in our studies, but 8918 may help us understand more about the 
biochemistry of these two products.  
pptT expression is likely downregulated during non-replication5, and the 
enzyme is crucial for the production of a number of lipids during replication. We were 
unable to conclusively identify if mycobactin was reduced in our lipidomic analysis, 
largely due to the unavailability of standards to compare peaks with. PptT activates 
MtbB and MtbE, which are involved in mycobactin synthesis4, so we would expect 
that 8918 could result in decreased mycobactin synthesis. We are interested in 
pursuing this hypothesis further and doing a more detailed analysis of mycobactin 
levels after 8918 exposure, because mycobactin is an important aspect of in vivo Mtb 
viability, especially when the bacteria are sequestered in iron-poor granulomas. PptT 
may not be utilized during non-replication, but if 8918 can reduce the production of 
mycobactins then it may be able to reduce the viability of cells even during non-
replication. The apparent ability of 8918 to enter the cells or at least stick to the 
membrane, as indicated by carryover during experiments, may benefit this hypothesis. 
Concentrations of 8918 could potentially be high around the bacteria for extended 
periods of time if structure metabolism could be minimized. Activity of a PptT 
inhibitor might also be more potent if we can understand more about PptH to exploit 
the relationship between the two enzymes during treatment. 
Our confirmation of rv2795c as a phosphopantetheinyl hydrolase was 
significant for a number of reasons. We first were able to classify an enzyme of 
unknown function, which is a small step in better understanding the biology of Mtb. 
Additionally, our identification of the activity of PptH represented a huge step in the 
study of similar acyl carrier protein hydrolase enzymes, as these enzymes have never 
been demonstrated in vivo. We can use PptH and 8918 as tools to understand more 
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about this puzzling biological process, which at first glance appears to be deleterious 
to the cells. The presence of functionally homologous enzymes in different species and 
the conservation of PptH among Mycobacteria indicate that this reaction may be 
important for processes that we do not yet understand. Finally, PptH is involved in a 
novel mechanism of resistance. Its involvement as an antagonist to the target of a 
small molecule, and the finding that loss of function of PptH can confer high-level 
8918 resistance to Mtb represents a new mechanism of antimicrobial resistance.  
The evidence taken together, makes a strong argument for the utility of PptT as 
a drug target. Mtb appears to be vulnerable to PptT inhibition during in vivo infection, 
even when PptT is only partially inhibited and the compound is being rapidly 
metabolized. Additionally, a more potent inhibitor may not be dependent on the 
activity of PptH, and the frequency of resistance would then be about 10x lower, in the 
same range as RIF. Because PptT is not yet a drug target, an inhibitor would be 
effective on MDR and XDR TB. We also infer that a PptT inhibitor would be highly 
specific to Mycobacteria, which is a greatly desired trait for Mtb drugs, in part due to 
the extended time for treatment. It is also possible due to the high structural homology 
between PptT in Mycobacteria that a PptT inhibitor could be used for treatment of 
Leprosy as well as for TB.  
 This project also exemplified the utility of studying the activity of small 
molecules on bacteria, as during the course of our investigation we identified many 
different new questions and avenues of research related to the biology that 8918 
uncovered. We have also identified a novel mechanism of resistance, in which a loss 
of function in an antagonistic enzyme results in high-level resistance to an inhibitor. 
This mechanism of resistance opened the door to a relatively unexplored area of 
biochemistry, as Rv2795c was previously an enzyme of unknown function, and the 
functional role of a phosphopantetheinyl hydrolase is not understood. Our toolbox of 
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the PptH knockout and the accompanying complement may be extremely useful in 
probing the relationship between PptT and PptH, as well as the function of PptH 
during Mtb survival in various conditions.  
 
Future Directions 
Many questions were generated in the course of this project about the role of PptH and 
its relationship to PptT, and what role PptH has during normal cell metabolism, 
especially during infection. We hypothesized that because PptH can deplete active 
precursors of important cell membrane lipids, we may be able to observe differences 
in membrane permeability between the knockouts and WT. We have examined the 
permeability of the membrane in WT, ΔpptH, and ΔpptH:pptH in an ethidium 
bromide uptake assay, and observed that both the knockout and the complement are 
more permeable than WT Mtb (Figure 1).  
 
Figure 1: Permeability assay of WT, KO, and complemented KO strains.  
Ethidium bromide uptake of WT (black) ΔpptH (blue) and ΔpptH:pptH (red). Baseline 
fluorescence is shown in grey.  
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 This indicates that PptH may be involved in membrane permeability, perhaps 
in regulating membrane lipid turnover in some way. The complement may be slightly 
less permeable than the full knockout, but it seems apparent that the reintroduction of 
the WT PptH enzyme is not sufficient to restore normal membrane function. Our 
initial determination of normal PptH activity was based on the MIC90 of 8918. As a 
result our complement may represent a WT-like phenotype in response to 8918, but 
the actual levels of PptT and PptH may not be representative of true WT. We 
hypothesize that for 8918 to have activity, PptT and PptH must be in some sort of 
balance; the complement may restore this relative balance but the actual activity may 
be higher which could impact the permeability of the membrane. It is also possible 
that if the ΔpptH strain has a hyperpermeable membrane, more 8918 can get in, but 
PptT is slightly overexpressed due to the SD3 translation initiation site, and the 
complement is also slightly overexpressing PptH with the end result having a similar 
MIC to the WT strain, despite the higher relative abundance of 8918 within the cell. 
 This experiment would be interesting to repeat and include the H246N PptH 
mutants, as well as the KO2 strain that was less resistant to 8918 than the KO1, and 
one of the complemented strains that was hypersensitive to 8918. We may be able to 
infer more about the balance of PptH and PptT by using these strains, which we think 
have varying balances of PptH and PptT. We may find that strains hypersensitive to 
8918−which we rationalized as functional overexpression of PptH−are less permeable 
than WT, which may implicate PptH in cell membrane turnover. Additionally, testing 
the H246N mutant that we have shown to be LOF and functionally identical to the 
knockout in regards to 8918 activity, might confirm whether the permeability that we 
observe is related to the loss of pptH, or if it might be related to a functional 
overexpression of pptT because of the SD3 translation initiation site controlling the 
expression of pptT. Solidifying the relationship between ΔpptH and membrane 
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permeability may expose a biological explanation for the enzyme, and rationalize a 
reason why it is expressed.  
 The MIC of WT, pptHH246N, pptTW170S, ΔpptH and ΔpptH:pptH against 8918 
have been discussed. We observed that the MIC90 for 8918 on WT was around 3.2 
µM, with the complement around 2.7 µM. By contrast, the 2 mutants were extremely 
resistant, though some inhibition (reaching MIC50 at the highest dose tested) could be 
observed, and the KO was fully resistant. We also observed throughout the course of 
the project that lidamidine’s apparent inactivity on whole Mtb was not very well 
confirmed by in vitro assays, as the WT PptT enzyme was inhibited by lidamidine to a 
degree that did not correlate with the in vivo activity observed. Interestingly, when 
lidamidine was tested at high concentrations we saw WT was only sensitive at very 
high doses (as described), only reaching an MIC50 at 125 µM (Figure 2A), but that the 
knockout and pptT mutant were fully resistant even at high doses, while the pptH 
mutant was slightly less resistant at the highest dose tested (Figure 2B-D). Finally, we 
observed that the complement appeared to be hypersensitive to lidamidine; though it 
did not pass an MIC50, it reached MIC50 at 10 µM as opposed to 125 µM in WT 
(Figure 2E). 
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Figure 2: MIC of 8918 (black) and lidamidine (red) in (A) WT strain (B) 
pptHH246N, (C) pptTW170S (D) ΔpptH and (E) ΔpptH:pptH. 
 
 This result may be an aspect of the hyperpermeability of the membrane in the 
complement combined with the large degree of accumulation of lidamidine within or 
around the cells. We are very interested in understanding more about how PptH 
interacts with membrane lipids and how it can impact membrane fluidity and 
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permeability, especially during exposure to stress. The impermeability of the Mtb 
membrane during non-replication has been associated with its ability to survive harsh 
conditions6. We hypothesize that PptH may be involved in mediating the 
impermeability of the membrane, or perhaps the recycling of membrane components 
during dormancy. In this way PptH may be conditionally essential only during times 
in which Mtb needed to cycle from replicating to non-replicating states. It would be 
interesting to compare the accumulation of lidamidine and 8918 within MT and WT 
cells as we did previously for metabolomics. We may see that that there is a drastic 
change in the accumulation in the ΔpptH:pptH strain, as the EtBr experiment indicated 
that the membrane is very permeable but that PptH is still active. It is very interesting 
that the ΔpptH:pptH strain is hypersusceptible to lidamidine and the differences in 
membrane permeability and accumulation may be informative. We may be able to 
target experiments investigating any conditional essentiality by learning more about 
the impact pptH modification has on the membrane.  
 In probing further into the activity of the pptH knockout during in vivo 
infection, we wanted to know if the ΔpptH strain remained resistant to 8918 treatment 
during infection, and if ΔpptH had a growth defect during mouse infection. We 
observed that during infection of primary murine bone marrow derived macrophages 
at a multiplicity of infection (MOI) of 0.1, ΔpptH was resistant to 8918 inhibition, 
while the WT and complement strains were not at 2 different concentrations of 8918 
(Figure 3A-B).  Xiuju Jiang conducted an aerosol mouse infection using WT Mtb, as 
well as the ΔpptH and ΔpptH:pptH strain. The summary of her findings can be found 
in Figure 3C.  
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Figure 3: Graphs of ΔpptH, WT, and complement in macrophage and mouse 
infection. (A) shows the CFU/mL of WT H37Rv (black line) compared to 8918 
treated (black dashed line), ΔpptH (blue line) vs 8918 treated (blue dashed line) and 
ΔpptH:pptH (red line) vs 89818 treated (red dashed line) recovered after a multiplicity 
of infection of 0.1, and 10 µM 8918. (B) shows the CFU/mL of WT H37Rv (black 
line) compared to 8918 treated (black dashed line), ΔpptH (blue line) vs 8918 treated 
(blue dashed line) and ΔpptH:pptH (red line) vs 89818 treated (red dashed line) 
recovered after a multiplicity of infection of 0.1, and 1 µM 8918. (C) shows the 
Cfu/lung recovered from a mouse infection of B6 mice with WT H37Rv (blue line), 
ΔpptH (orange), and ΔpptH :pptH (grey) over the course of 180 days. Mouse infection 
conducted by Xiuju Jiang. 
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Figure 3 continued 
C. 
  
 The macrophage experiment shown in Figure 3A and B supported our in vitro 
findings that the ΔpptH strain was resistant to 8918, and showed that it was in vivo 
resistant as well. The mouse experiment indicated that the ΔpptH strain did not have a 
growth defect during mouse infection. This finding conflicts with some of our 
hypotheses about potential conditional essentiality of pptH, though in this experiment 
the uptake and bacterial burden of Mtb for all 3 strains was very low. We know from 
our whole genome resequencing that the ΔpptH and ΔpptH:pptH strains are PDIM 
deficient, which generally leads to lower CFU burden during infection, as Mtb with 
PDIM deficiencies is less virulent. It is possible that reduced virulence may mask 
differences between the WT and pptH KO, though it may also be that in this infection 
model pptH is not essential. PDIM mutations arise rapidly during in vitro culturing of 
Mtb, and the number of passages on solid and liquid media necessary to generate a 
KO and complement make it challenging if not impossible to maintain PDIM during 
the process. If pptH is not conditionally essential during infection, it still is an enigma 
	132		
as to why Mtb would express it all. We still hypothesize that pptH performs some 
useful role within Mtb that provides a rationale for its conservation, and it appears that 
our complement--which we hypothesized may have a slight overexpression of pptH—
may be hypersensitive to 8918 during macrophage infection, which may also help us 
learn more about the activity of pptH. 
The presence of pptT and pptH in the same operon is also interesting to us. We 
are interested in knowing more about how the two enzymes are regulated and in what 
conditions expression may be modulated to benefit the cell. It seems clear that PptH 
can be toxic for Mtb if it is overexpressed, and that the balance of PptT and PptH can 
have interesting impacts on membrane permeability and susceptibility to lidamidine. 
We are planning qRT-PCR to learn more about how the two genes may be related, and 
under what conditions pptH might be expressed, and if it might sometimes be 
expressed over pptT. It would also be interesting to examine the pptH knock out 
strains that carried silent mutations in pptT. It has been shown that silent mutations can 
change the rate or degree of gene expression7,8. If the silent mutations we observed in 
the knockouts do modify the expression of pptT, it could be further evidence that the 
regulation and balance of pptT and pptH is very important to maintain.  
As one more question, we are interested in understanding more about other 
possible purposes for PptH. We have seen some evidence that it may have a role in the 
composition of the membrane. But we would also like to know more about what it 
does. For instance, what enzymes can it dephosphopantetheinylate? We have shown 
that it is active on AcpM but we don’t know how active it would be on other enzymes 
that are phosphopantetheinylated. Is it active on any protein that has ppt? Is it specific 
to the proteins activated by PptT? Proteomic investigation of the pptH knockout may 
be informative. Similarly, there is some evidence that CoA can be synthesized from 
extracellular phosphopantetheine76,97. Maybe PptH has some role in this process, 
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especially if CoA sometimes needs to be used as a post-translational modification89. It 
might be informative to add radiolabeled phosphopantetheine in the WT and KO and 
try to determine if there are differences in the metabolism of the extracellular ppt.  
Our discovery of the activity of PptH answered one question, but raised many 
more. Knowing what reaction an enzyme catalyzes is only a small piece of the puzzle, 
and how the enzyme fits into the complex web of cell biochemistry is a more 
complicated question. PptH and its relationship with PptT has opened up an extensive 
list of questions that hopefully will reveal more about Mtb and 
phosphopantetheinylation as a cellular process.  
 
Materials and Methods 
Ethidium Bromide Uptake Assay: 
Mtb H37Rv was grown in 7H9 supplemented with 10% Middlebrook OADC and 
0.2% tyloxapol until they reached an OD580 between 0.6 and 0.8. The cells were 
washed once in PBS containing 0.2% tyloxapol and adjusted to OD580 of 0.8. Glucose 
was added to a final concentration of 0.4%. Ethidium Bromide (EtBr) was prepared to 
4 μg/mL in PBS with 0.2% tyloxapol and 100 μL were added to each reaction well. 
100 μL of Mtb were added to each well and mixed (final OD580 0.4). The plates were 
quickly transferred to the prewarmed (37 °C) plate reader, and the plates were read 
every minute for 60 minutes at an excitation of 530 nM and an emission of 590 nM.  
Macrophage infection: 
Bone marrow macrophages were isolated from B6 mouse femurs and differentiated in 
20% LCM and DMEM complete. They were seeded to a density of 2.5x105 per well in 
48 well plates, and infection was done at an MOI of 0.1 for 4 hours of exposure. After 
4 hours the cells were washed with PBS twice, day 0 macrophages were lysed and 
plated, and 10% LCM and DMEM complete added back to the remaining. 8918 was 
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given 24 hours later (day 1), and replaced on day 3, in new 10% LCM and DMEM 
complete.  
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